GUIS Sandrine
Publications :
180164
GUIS
1
harvard-cite-them-right-no-et-al
50
date
desc
year
2637
https://crmbm.univ-amu.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A50%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%227FHVK5PB%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guenoun%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuenoun%2C%20D.%2C%20Wirth%2C%20T.%2C%20Roche%2C%20D.%2C%20Michel%2C%20C.P.%2C%20Daud%26%23xE9%3B%2C%20P.%2C%20Ogier%2C%20A.C.%2C%20Chagnaud%2C%20C.%2C%20Mattei%2C%20J.P.%2C%20Pini%2C%20L.%2C%20Guye%2C%20M.%2C%20Ollivier%2C%20M.%2C%20Bendahan%2C%20D.%20and%20Guis%2C%20S.%20%282023%29%20%26%23x201C%3BUltra-high%20field%20magnetic%20resonance%20imaging%20of%20the%20quadriceps%20tendon%20enthesis%20in%20healthy%20subjects%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BSurgical%20and%20Radiologic%20Anatomy%26lt%3B%5C%2Fi%26gt%3B%2C%2045%288%29%2C%20pp.%201049%26%23x2013%3B1054.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00276-023-03175-y%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00276-023-03175-y%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ultra-high%20field%20magnetic%20resonance%20imaging%20of%20the%20quadriceps%20tendon%20enthesis%20in%20healthy%20subjects%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daphne%22%2C%22lastName%22%3A%22Guenoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theo%22%2C%22lastName%22%3A%22Wirth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Roche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%20P.%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Daud%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%20C.%22%2C%22lastName%22%3A%22Ogier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauriane%22%2C%22lastName%22%3A%22Pini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Ollivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22Although%20enthesitis%20is%20a%20hallmark%20of%20several%20rheumatologic%20conditions%2C%20current%20imaging%20methods%20are%20still%20unable%20to%20characterize%20entheses%20changes%20because%20of%20the%20corresponding%20short%20transverse%20relaxation%20times%20%28T2%29.%20A%20growing%20number%20of%20MR%20studies%20have%20used%20Ultra-High%20Field%20%28UHF%29%20MRI%20in%20order%20to%20assess%20low-T2%20tissues%20e.g.%2C%20tendon%20but%20never%20in%20humans.%20The%20purpose%20of%20the%20present%20study%20was%20to%20assess%20in%20vivo%20the%20enthesis%20of%20the%20quadriceps%20tendon%20in%20healthy%20subjects%20using%20UHF%20MRI.%22%2C%22date%22%3A%222023-08-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00276-023-03175-y%22%2C%22ISSN%22%3A%221279-8517%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00276-023-03175-y%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%226BEMAGEW%22%2C%2248SZ2I24%22%2C%22ZP8JD3DQ%22%2C%22ACGLJ26R%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-12-05T16%3A12%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22K7XR38KN%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Trojani%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTrojani%2C%20M.-C.%2C%20Chorin%2C%20F.%2C%20Gerus%2C%20P.%2C%20Breuil%2C%20V.%2C%20Michel%2C%20C.%2C%20Guis%2C%20S.%2C%20Bendahan%2C%20D.%20and%20Roux%2C%20C.%20%282022%29%20%26%23x201C%3BConcentric%20or%20eccentric%20physical%20activity%20for%20patients%20with%20symptomatic%20osteoarthritis%20of%20the%20knee%3A%20a%20randomized%20prospective%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BTherapeutic%20Advances%20in%20Musculoskeletal%20Disease%26lt%3B%5C%2Fi%26gt%3B%2C%2014%2C%20p.%201759720X221102805.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1759720X221102805%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1759720X221102805%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Concentric%20or%20eccentric%20physical%20activity%20for%20patients%20with%20symptomatic%20osteoarthritis%20of%20the%20knee%3A%20a%20randomized%20prospective%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Charlotte%22%2C%22lastName%22%3A%22Trojani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Chorin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Gerus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Breuil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constance%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Roux%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Knee%20osteoarthritis-related%20pain%20limits%20physical%20function%20and%20leads%20to%20functional%20disability.%20Physical%20activity%20is%20one%20of%20the%20central%20recommendations%20for%20the%20management%20of%20knee%20osteoarthritis.%20Although%20concentric%20muscle%20activities%20are%20often%20preferred%20to%20eccentric%20ones%2C%20the%20corresponding%20rationale%20remains%20controversial.%5CnOBJECTIVE%3A%20To%20explore%20the%20effect%20of%20a%206-week%20exercise%20program%20on%20function%2C%20pain%2C%20and%20performance%20in%20patients%20with%20symptomatic%20knee%20osteoarthritis.%5CnMETHODS%3A%20Patients%20with%20symptomatic%20knee%20osteoarthritis%20were%20included%20in%20the%20prospective%20EX-ART%20project%20%28Walking%20performance%20in%20osteoARThritic%20subjects%3A%20effect%20of%20an%20ECCentric%20muscle%20strengthening%20program%29%20and%20randomized%20in%20a%206-week%20rehabilitation%20program%20including%20either%20eccentric%20or%20concentric%20activities.%20Metrics%20of%20interest%20chosen%20as%20end%20points%20measured%20before%20and%20after%20the%20rehabilitation%20were%20WOMAC%20score%2C%20pain%2C%20and%20muscular%20performance%20%28quadriceps%20power%20PMAX%20and%20contraction%20strength%20MMAX%29.%20MRI%20was%20also%20used%20to%20assess%20muscle%20volume%20and%20fat%20infiltration%20changes.%5CnRESULTS%3A%2030%20patients%20were%20included%20in%20each%20group%3B%20mean%20age%20was%2074%20%28%5Cu00b17.6%29%3B%2069%25%20were%20women.%20At%20week%206%2C%20both%20groups%20showed%20a%20significant%20improvement%20in%20the%20WOMAC%20without%20difference%20between%20the%20two%20groups%20%28p%5Cu2009%3D%5Cu20090.7%29.%20No%20difference%20between%20the%20two%20groups%20was%20identified%20for%20the%20pain%20reduction%20%28p%5Cu2009%3D%5Cu20090.7%29.%20A%20significant%20improvement%20in%20the%20change%20in%20PMAX%20and%20MMAX%20at%20high%20velocity%20%28p%5Cu2009%3D%5Cu20090.001%20and%20p%5Cu2009%3D%5Cu20090.002%29%20was%20observed%20in%20the%20eccentric%20group%20only.%20A%20vastus%20medialis%20hypertrophy%20was%20quantified%20in%20the%20eccentric%20group%20only%20%28p%5Cu2009%3D%5Cu20090.002%29%2C%20whereas%20fat%20infiltration%20in%20the%20quadriceps%20muscles%20was%20unchanged.%5CnCONCLUSION%3A%20Physical%20activity%2C%20whether%20eccentric%20or%20concentric%2C%20has%20a%20benefit%20on%20function%20and%20pain%20in%20patients%20with%20symptomatic%20knee%20osteoarthritis.%20A%20few%20differences%20have%20been%20identified%20between%20the%20two%20types%20of%20rehabilitation.%20More%20particularly%2C%20a%20gain%20in%20muscle%20performance%20and%20vastus%20medialis%20volume%20was%20found%20with%20eccentric%20rehabilitation%20only.%5CnREGISTRATION%3A%20www.ClinicalTrials.gov%2C%20registration%20number%20NCT03167502.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1759720X221102805%22%2C%22ISSN%22%3A%221759-720X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22RUHIKNT6%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guedj%20et%20al.%22%2C%22parsedDate%22%3A%222021-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuedj%2C%20E.%2C%20Campion%2C%20J.Y.%2C%20Dudouet%2C%20P.%2C%20Kaphan%2C%20E.%2C%20Bregeon%2C%20F.%2C%20Tissot-Dupont%2C%20H.%2C%20Guis%2C%20S.%2C%20Barthelemy%2C%20F.%2C%20Habert%2C%20P.%2C%20Ceccaldi%2C%20M.%2C%20Million%2C%20M.%2C%20Raoult%2C%20D.%2C%20Cammilleri%2C%20S.%20and%20Eldin%2C%20C.%20%282021%29%20%26%23x201C%3B18F-FDG%20brain%20PET%20hypometabolism%20in%20patients%20with%20long%20COVID%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Nuclear%20Medicine%20and%20Molecular%20Imaging%26lt%3B%5C%2Fi%26gt%3B%2C%2048%289%29%2C%20pp.%202823%26%23x2013%3B2833.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00259-021-05215-4%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00259-021-05215-4%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%2218F-FDG%20brain%20PET%20hypometabolism%20in%20patients%20with%20long%20COVID%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Guedj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Campion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Dudouet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Kaphan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bregeon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Tissot-Dupont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Barthelemy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Habert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Ceccaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Million%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Raoult%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Cammilleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Eldin%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20In%20the%20context%20of%20the%20worldwide%20outbreak%20of%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20%28SARS-CoV-2%29%2C%20some%20patients%20report%20functional%20complaints%20after%20apparent%20recovery%20from%20COVID-19.%20This%20clinical%20presentation%20has%20been%20referred%20as%20%26quot%3Blong%20COVID.%26quot%3B%20We%20here%20present%20a%20retrospective%20analysis%20of%2018F-FDG%20brain%20PET%20of%20long%20COVID%20patients%20from%20the%20same%20center%20with%20a%20biologically%20confirmed%20diagnosis%20of%20SARS-CoV-2%20infection%20and%20persistent%20functional%20complaints%20at%20least%203%5Cu00a0weeks%20after%20the%20initial%20infection.%5CnMETHODS%3A%20PET%20scans%20of%2035%20patients%20with%20long%20COVID%20were%20compared%20using%20whole-brain%20voxel-based%20analysis%20to%20a%20local%20database%20of%2044%20healthy%20subjects%20controlled%20for%20age%20and%20sex%20to%20characterize%20cerebral%20hypometabolism.%20The%20individual%20relevance%20of%20this%20metabolic%20profile%20was%20evaluated%20to%20classify%20patients%20and%20healthy%20subjects.%20Finally%2C%20the%20PET%20abnormalities%20were%20exploratory%20compared%20with%20the%20patients%26%23039%3B%20characteristics%20and%20functional%20complaints.%5CnRESULTS%3A%20In%20comparison%20to%20healthy%20subjects%2C%20patients%20with%20long%20COVID%20exhibited%20bilateral%20hypometabolism%20in%20the%20bilateral%20rectal%5C%2Forbital%20gyrus%2C%20including%20the%20olfactory%20gyrus%3B%20the%20right%20temporal%20lobe%2C%20including%20the%20amygdala%20and%20the%20hippocampus%2C%20extending%20to%20the%20right%20thalamus%3B%20the%20bilateral%20pons%5C%2Fmedulla%20brainstem%3B%20the%20bilateral%20cerebellum%20%28p-voxel%20%26lt%3B%5Cu20090.001%20uncorrected%2C%20p-cluster%20%26lt%3B%5Cu20090.05%20FWE-corrected%29.%20These%20metabolic%20clusters%20were%20highly%20discriminant%20to%20distinguish%20patients%20and%20healthy%20subjects%20%28100%25%20correct%20classification%29.%20These%20clusters%20of%20hypometabolism%20were%20significantly%20associated%20with%20more%20numerous%20functional%20complaints%20%28brainstem%20and%20cerebellar%20clusters%29%2C%20and%20all%20associated%20with%20the%20occurrence%20of%20certain%20symptoms%20%28hyposmia%5C%2Fanosmia%2C%20memory%5C%2Fcognitive%20impairment%2C%20pain%20and%20insomnia%29%20%28p%5Cu2009%26lt%3B%5Cu20090.05%29.%20In%20a%20more%20preliminary%20analysis%2C%20the%20metabolism%20of%20the%20frontal%20cluster%20which%20included%20the%20olfactory%20gyrus%20was%20worse%20in%20the%207%20patients%20treated%20by%20ACE%20drugs%20for%20high%20blood%20pressure%20%28p%5Cu2009%3D%5Cu20090.032%29%2C%20and%20better%20in%20the%203%20patients%20that%20had%20used%20nasal%20decongestant%20spray%20at%20the%20infectious%20stage%20%28p%5Cu2009%26lt%3B%5Cu20090.001%29.%5CnCONCLUSION%3A%20This%20study%20demonstrates%20a%20profile%20of%20brain%20PET%20hypometabolism%20in%20long%20COVID%20patients%20with%20biologically%20confirmed%20SARS-CoV-2%20and%20persistent%20functional%20complaints%20more%20than%203%5Cu00a0weeks%20after%20the%20initial%20infection%20symptoms%2C%20involving%20the%20olfactory%20gyrus%20and%20connected%20limbic%5C%2Fparalimbic%20regions%2C%20extended%20to%20the%20brainstem%20and%20the%20cerebellum.%20These%20hypometabolisms%20are%20associated%20with%20patients%26%23039%3B%20symptoms%2C%20with%20a%20biomarker%20value%20to%20identify%20and%20potentially%20follow%20these%20patients.%20The%20hypometabolism%20of%20the%20frontal%20cluster%2C%20which%20included%20the%20olfactory%20gyrus%2C%20seems%20to%20be%20linked%20to%20ACE%20drugs%20in%20patients%20with%20high%20blood%20pressure%2C%20with%20also%20a%20better%20metabolism%20of%20this%20olfactory%20region%20in%20patients%20using%20nasal%20decongestant%20spray%2C%20suggesting%20a%20possible%20role%20of%20ACE%20receptors%20as%20an%20olfactory%20gateway%20for%20this%20neurotropism.%22%2C%22date%22%3A%222021-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00259-021-05215-4%22%2C%22ISSN%22%3A%221619-7089%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%2C%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-11-12T11%3A08%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22XLRI6EGB%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Molto%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMolto%2C%20A.%2C%20Gossec%2C%20L.%2C%20Poiraudeau%2C%20S.%2C%20Claudepierre%2C%20P.%2C%20Soubrier%2C%20M.%2C%20Fayet%2C%20F.%2C%20Wendling%2C%20D.%2C%20Gaudin%2C%20P.%2C%20Dernis%2C%20E.%2C%20Guis%2C%20S.%2C%20Pouplin%2C%20S.%2C%20Ruyssen-Witrand%2C%20A.%2C%20Chales%2C%20G.%2C%20Mariette%2C%20X.%2C%20Beauvais%2C%20C.%2C%20Combe%2C%20B.%2C%20Flipo%2C%20R.-M.%2C%20Richette%2C%20P.%2C%20Chary-Valckenaere%2C%20I.%2C%20Saraux%2C%20A.%2C%20Sibilia%2C%20J.%2C%20Schaeverbeke%2C%20T.%20and%20Dougados%2C%20M.%20%282021%29%20%26%23x201C%3BEvaluation%20of%20the%20impact%20of%20a%20nurse-led%20program%20of%20patient%20self-assessment%20and%20self-management%20in%20axial%20spondyloarthritis%3A%20results%20of%20a%20prospective%2C%20multicentre%2C%20randomized%2C%20controlled%20trial%20%28COMEDSPA%29%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BRheumatology%20%28Oxford%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%2060%282%29%2C%20pp.%20888%26%23x2013%3B895.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Frheumatology%5C%2Fkeaa480%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Frheumatology%5C%2Fkeaa480%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20the%20impact%20of%20a%20nurse-led%20program%20of%20patient%20self-assessment%20and%20self-management%20in%20axial%20spondyloarthritis%3A%20results%20of%20a%20prospective%2C%20multicentre%2C%20randomized%2C%20controlled%20trial%20%28COMEDSPA%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Molto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gossec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Poiraudeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Claudepierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Soubrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Fayet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Wendling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Dernis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Pouplin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Ruyssen-Witrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Chales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Mariette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Beauvais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Combe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ren%5Cu00e9-Marc%22%2C%22lastName%22%3A%22Flipo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Richette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Chary-Valckenaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Saraux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Sibilia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Schaeverbeke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Dougados%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20evaluate%20the%20impact%20of%20a%20nurse-led%20program%20of%20self-management%20and%20self-assessment%20of%20disease%20activity%20in%20axial%20spondyloarthritis.%5CnMETHODS%3A%20Prospective%2C%20randomized%2C%20controlled%2C%20open%2C%2012-month%20trial%20%28NCT02374749%29.%20Participants%20were%20consecutive%20axial%20spondyloarthritis%20patients%20%28according%20to%20the%20rheumatologist%29%20and%20nurses%20having%20participated%20in%20a%201-day%20training%20meeting.%20The%20program%20included%20self-management%3A%20educational%20video%20and%20specific%20video%20of%20graduated%2C%20home-based%20exercises%20for%20patients%3B%20and%20self-assessment%3A%20video%20presenting%20the%20rationale%20of%20tight%20monitoring%20of%20disease%20activity%20with%20composite%20scores%20%28Ankylosing%20Spondylitis%20Disease%20activity%20Score%2C%20ASDAS%5C%2FBath%20Ankyslosing%20Spondylitis%20Disease%20Activity%20Index%2C%20BASDAI%29.%20The%20nurse%20trained%20patients%20to%20collect%2C%20calculate%20and%20report%20%28monthly%29%20ASDAS%5C%2FBASDAI.%20Treatment%20allocation%20was%20by%20random%20allocation%20to%20this%20program%20or%20a%20comorbidities%20assessment%20%28not%20presented%20here%20and%20considered%20here%20as%20the%20control%20group%29.%5CnRESULTS%3A%20A%20total%20of%20502%20patients%20%28250%20and%20252%20in%20the%20active%20and%20control%20groups%2C%20respectively%29%20were%20enrolled%20%28age%3A%2046.7%20%2812.2%29%5Cu2009years%2C%20male%20gender%3A%2062.7%25%2C%20disease%20duration%3A%2013.7%20%2811.0%29%5Cu2009years%29.%20After%20the%20one-year%20follow-up%20period%2C%20the%20adherence%20to%20the%20self-assessment%20program%20was%20considered%20good%20%28i.e.%2079%25%20reported%20scores%20%26gt%3B6%20times%29.%20Despite%20a%20lack%20of%20statistical%20significance%20in%20the%20primary%20outcome%20%28e.g.%20coping%29%20there%20was%20a%20statistically%20significant%20difference%20in%20favor%20of%20this%20program%20for%20the%20following%20variables%3A%20change%20in%20BASDAI%2C%20number%20and%20duration%20of%20the%20home%20exercises%20in%20the%20active%20group%2C%20and%20physical%20activity%20%28international%20physical%20activity%20score%2C%20IPAQ%29.%5CnCONCLUSION%3A%20This%20study%20suggests%20a%20short-term%20benefit%20of%20a%20nurse-led%20program%20on%20self-management%20and%20self-assessment%20for%20disease%20activity%20in%20a%20young%20axial%20spondyloarthritis%20population%20in%20terms%20of%20disease%20activity%2C%20exercises%20and%20physical%20activity.%22%2C%22date%22%3A%222021-02-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Frheumatology%5C%2Fkeaa480%22%2C%22ISSN%22%3A%221462-0332%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A40%3A52Z%22%7D%7D%2C%7B%22key%22%3A%226B4PH48L%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Soldati%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSoldati%2C%20E.%2C%20Escoffier%2C%20L.%2C%20Gabriel%2C%20S.%2C%20Ogier%2C%20A.C.%2C%20Chagnaud%2C%20C.%2C%20Mattei%2C%20J.P.%2C%20Cammilleri%2C%20S.%2C%20Bendahan%2C%20D.%20and%20Guis%2C%20S.%20%282021%29%20%26%23x201C%3BAssessment%20of%20in%20vivo%20bone%20microarchitecture%20changes%20in%20an%20anti-TNF%26%23x3B1%3B%20treated%20psoriatic%20arthritic%20patient%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BPloS%20One%26lt%3B%5C%2Fi%26gt%3B%2C%2016%285%29%2C%20p.%20e0251788.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0251788%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0251788%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessment%20of%20in%20vivo%20bone%20microarchitecture%20changes%20in%20an%20anti-TNF%5Cu03b1%20treated%20psoriatic%20arthritic%20patient%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Soldati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Escoffier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Gabriel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Augustin%20C.%22%2C%22lastName%22%3A%22Ogier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20P.%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Cammilleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Psoriatic%20arthritis%20%28PsA%29%20is%20an%20inflammatory%20rheumatic%20disease%2C%20mediated%20in%20part%20by%20TNF%5Cu03b1%20and%20associated%20with%20bone%20loss.%20Anti-TNF%5Cu03b1%20treatment%20should%20inhibit%20this%20phenomenon%20and%20reduce%20the%20systemic%20bone%20loss.%20Ultra-high%20field%20MRI%20%28UHF%20MRI%29%20may%20be%20used%20to%20quantify%20bone%20microarchitecture%20%28BM%29%20in-vivo.%20In%20this%20study%2C%20we%20quantified%20BM%20using%20UHF%20MRI%20in%20a%20PsA%20patient%20and%20followed%20up%20the%20changes%20related%20to%20anti-TNF%5Cu03b1%20treatment.%5CnSUBJECTS%20AND%20METHODS%3A%20A%20non-treated%20PsA%20patient%20with%20knee%20arthritis%20and%207%20gender-matched%20controls%20were%20scanned%20using%20a%20gradient%20re-echo%20sequence%20at%20UHF%20MRI.%20After%20a%20year%20of%20Adalimumab%20treatment%2C%20the%20patient%20underwent%20a%20second%20UHF%20MRI.%20A%20PET-FNa%20imaging%20was%20performed%20before%20and%20after%20treatment%20to%20identify%20and%20localize%20the%20abnormal%20metabolic%20areas.%20BM%20was%20characterized%20using%20typical%20morphological%20parameters%20quantified%20in%2032%20regions%20of%20interest%20%28ROIs%29%20located%20in%20the%20patella%2C%20proximal%20tibia%2C%20and%20distal%20femur.%5CnRESULTS%3A%20Before%20treatment%2C%20the%20BM%20parameters%20were%20statistically%20different%20from%20controls%20in%2024%5C%2F32%20ROIs%20with%20differences%20reaching%20up%20to%2038%25.%20After%20treatment%2C%20BM%20parameters%20were%20normalized%20for%2015%20out%20of%2024%20ROIs.%20The%20hypermetabolic%20areas%20disclosed%20by%20PET-FNa%20before%20the%20treatment%20partly%20resumed%20after%20the%20treatment.%5CnCONCLUSION%3A%20Thanks%20to%20UHF%20MRI%2C%20we%20quantified%20in%20vivo%20BM%20anomalies%20in%20a%20PsA%20patient%20and%20we%20illustrated%20a%20major%20reversion%20after%20one%20year%20of%20treatment.%20Moreover%2C%20BM%20results%20highlighted%20that%20the%20abnormalities%20were%20not%20only%20localized%20in%20hypermetabolic%20regions%20identified%20by%20PET-FNa%2C%20suggesting%20that%20the%20bone%20loss%20was%20global%20and%20not%20related%20to%20inflammation.%22%2C%22date%22%3A%222021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0251788%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22VJCS2Y4H%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Falgarone%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFalgarone%2C%20G.%2C%20Pamoukdjian%2C%20F.%2C%20Cailhol%2C%20J.%2C%20Giocanti-Auregan%2C%20A.%2C%20Guis%2C%20S.%2C%20Bousquet%2C%20G.%2C%20Bouchaud%2C%20O.%20and%20Seror%2C%20O.%20%282020%29%20%26%23x201C%3BLung%20ultrasound%20is%20a%20reliable%20diagnostic%20technique%20to%20predict%20abnormal%20CT%20chest%20scan%20and%20to%20detect%20oxygen%20requirements%20in%20COVID-19%20pneumonia%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAging%26lt%3B%5C%2Fi%26gt%3B%2C%2012%2820%29%2C%20pp.%2019945%26%23x2013%3B19953.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.18632%5C%2Faging.104150%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.18632%5C%2Faging.104150%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lung%20ultrasound%20is%20a%20reliable%20diagnostic%20technique%20to%20predict%20abnormal%20CT%20chest%20scan%20and%20to%20detect%20oxygen%20requirements%20in%20COVID-19%20pneumonia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Falgarone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Pamoukdjian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johann%22%2C%22lastName%22%3A%22Cailhol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Giocanti-Auregan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilhem%22%2C%22lastName%22%3A%22Bousquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Bouchaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Seror%22%7D%5D%2C%22abstractNote%22%3A%22COVID-19%20pneumonia%20can%20be%20severe%2C%20with%20an%20unpredictable%20evolution%20and%20high%20mortality%20prevalence%20in%20older%20patients.%20The%20diagnosis%20is%20usually%20performed%20by%20RT-PCR%20or%20CT%20chest%20scan.%20Lung%20ultrasonography%20%28LUS%29%20has%20been%20proposed%20as%20an%20alternative%20method%20to%20monitor%20patients%20with%20COVID-19%20pneumonia.%20To%20assess%20the%20diagnostic%20performance%20of%20LUS%2C%20we%20performed%20LUS%20using%20a%20portable%20device%20and%20adapting%20a%20protocol%20already%20used%20in%20Acute%20Respiratory%20Syndrome.%20We%20used%20the%20score%20obtained%20with%20the%20index%20we%20created%20to%20assess%20for%20LUS%20diagnostic%20performance%20as%20compared%20to%20lung%20CT%20chest%20scan%20and%20to%20predict%20for%20oxygen%20requirements.%20Daily%20bedside%20LUS%20was%20easy%20to%20perform%20and%20microbiologically%20safe.%20LUS%20was%2089%25%20sensitive%20and%20100%25%20specific%20in%20predicting%20CT%20chest%20scan%20abnormalities%2C%20and%2095%25%20sensitive%20and%2067%25%20specific%20in%20detecting%20oxygen%20requirements.%20This%20is%20the%20first%20report%20on%20the%20diagnostic%20performance%20of%20LUS%20as%20compared%20to%20CT%20chest%20scan%20for%20the%20diagnosis%20of%20COVID-19%20pneumonia%20and%20assessments%20of%20oxygen%20requirements%20by%20LUS.%20LUS%20could%20help%20in%20the%20orientation%20of%20dyspneic%20patients%20to%20intensive%20care.%20It%20could%20also%20be%20proposed%20when%20there%20is%20limited%20access%20to%20CT%20scan%20in%20the%20context%20of%20a%20pandemic%20crisis%2C%20or%20to%20implement%20clinical%20lung%20examinations%20for%20outpatient%20follow-up.%22%2C%22date%22%3A%22Oct%2030%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.18632%5C%2Faging.104150%22%2C%22ISSN%22%3A%221945-4589%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%2C%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22VCL9CRRT%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Molto%20et%20al.%22%2C%22parsedDate%22%3A%222020-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMolto%2C%20A.%2C%20Gossec%2C%20L.%2C%20Poiraudeau%2C%20S.%2C%20Claudepierre%2C%20P.%2C%20Soubrier%2C%20M.%2C%20Fayet%2C%20F.%2C%20Wendling%2C%20D.%2C%20Gaudin%2C%20P.%2C%20Dernis%2C%20E.%2C%20Guis%2C%20S.%2C%20Pouplin%2C%20S.%2C%20Ruyssen%2C%20A.%2C%20Chales%2C%20G.%2C%20Mariette%2C%20X.%2C%20Beauvais%2C%20C.%2C%20Combe%2C%20B.%2C%20Flipo%2C%20R.-M.%2C%20Richette%2C%20P.%2C%20Chary-Valckenaere%2C%20I.%2C%20Saraux%2C%20A.%2C%20Sibilia%2C%20J.%2C%20Schaeverbeke%2C%20T.%20and%20Dougados%2C%20M.%20%282020%29%20%26%23x201C%3BEvaluation%20of%20the%20impact%20of%20a%20nurse-led%20program%20of%20systematic%20screening%20of%20comorbidities%20in%20patients%20with%20axial%20spondyloarthritis%3A%20The%20results%20of%20the%20COMEDSPA%20prospective%2C%20controlled%2C%20one%20year%20randomized%20trial%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BSeminars%20in%20Arthritis%20and%20Rheumatism%26lt%3B%5C%2Fi%26gt%3B%2C%2050%284%29%2C%20pp.%20701%26%23x2013%3B708.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.semarthrit.2020.05.012%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.semarthrit.2020.05.012%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20the%20impact%20of%20a%20nurse-led%20program%20of%20systematic%20screening%20of%20comorbidities%20in%20patients%20with%20axial%20spondyloarthritis%3A%20The%20results%20of%20the%20COMEDSPA%20prospective%2C%20controlled%2C%20one%20year%20randomized%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Molto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gossec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Poiraudeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Claudepierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Soubrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Fayet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Wendling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Dernis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Pouplin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Ruyssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Chales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Mariette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Beauvais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Combe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ren%5Cu00e9-Marc%22%2C%22lastName%22%3A%22Flipo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Richette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Chary-Valckenaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Saraux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Sibilia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Schaeverbeke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Dougados%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20evaluate%20the%20impact%20of%20a%20nurse-led%20program%20of%20systematic%20screening%20for%20the%20management%20%28detection%5C%2Fprevention%29%20of%20comorbidities.%5CnMETHODS%3A%20Prospective%2C%20randomized%2C%20controlled%2C%20open%2C%2012-month%20trial%20%28NCT02374749%29.%5CnPARTICIPANTS%3A%20consecutive%20patients%20with%20axial%20Spondyloarthritis%20%28axSpA%29%20%28according%20to%20the%20rheumatologist%29%20THE%20PROGRAM%3A%20A%20nurse%20collected%20data%20on%20comorbidities%20during%20a%20specific%20outpatient%20visit.%20In%20the%20event%20of%20non-agreement%20with%20recommendations%2C%20the%20patient%20was%20informed%20and%20a%20specific%20recommendation%20was%20given%20to%20the%20patient%20%28orally%20and%20in%20a%20with%20a%20detailed%20written%20report%29.%20Patients%20were%20seen%20after%20one%20year%20in%20a%20nurse-led%20visit.%20TREATMENT%20ALLOCATION%3A%20random%20allocation%20%28i.e.%20either%20this%20program%20or%20an%20educational%20program%20not%20presented%20here%20and%20considered%20here%20as%20the%20control%20group%29.%5CnMAIN%20OUTCOME%3A%20change%20after%20one%20year%20of%20a%20weighted%20comorbidity%20management%20score%20%280%20to%20100%20where%200%3D%20optimal%20management%29.%5CnRESULTS%3A%20502%20patients%20were%20included%20%28252%20and%20250%20in%20the%20active%20and%20control%20groups%2C%20respectively%29%3A%20age%3A%2047%5Cu00b112%20years%2C%20male%20gender%3A%2063%25%2C%20disease%20duration%3A%2014%5Cu00b111y.%20After%20one%20year%2C%20no%20differences%20were%20observed%20in%20a%20weighted%20comorbidity%20management%20score.%20However%2C%20the%20number%20of%20patients%20in%20agreement%20with%20recommendations%20was%20significantly%20higher%20in%20the%20active%20group%20for%20vaccinations%20%28flu%20vaccination%3A%2028.6%25%20vs.%209.9%25%2C%20p%26lt%3B0.01%3B%20pneumococcal%20vaccination%3A40.0%25%20vs.%2021.1%25%2Cp%3D0.04%29%2C%20for%20cancer%20screening%20%28skin%20cancer%20screening%3A%2036.3%25%20vs.%2017.2%25%2C%20p%3D0.04%29%20and%20for%20osteoporosis%20%28bone%20densitometry%20performed%3A%2022.6%25%20vs.%208.7%25%2C%20p%26lt%3B0.01%3B%20Vitamin%20D%20supplementation%20initiation%3A%2051.9%25%20vs.%209.4%25%2C%20p%26lt%3B0.01%29.%5CnCONCLUSIONS%20AND%20RELEVANCE%3A%20This%20study%20suggests%20the%20short-term%20benefit%20of%20a%20single-visit%20nurse-led%20program%20for%20systematic%20screening%20of%20comorbidities%20for%20its%20management%20in%20agreement%20with%20recommendations%2C%20even%20in%20this%20young%20population%20of%20patients%20with%20axSpA.%22%2C%22date%22%3A%222020-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.semarthrit.2020.05.012%22%2C%22ISSN%22%3A%221532-866X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A40%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22RAQXVXL7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guenoun%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuenoun%2C%20D.%2C%20Pithioux%2C%20M.%2C%20Souplet%2C%20J.-C.%2C%20Guis%2C%20S.%2C%20Le%20Corroller%2C%20T.%2C%20Four%26%23xE9%3B%2C%20A.%2C%20Pauly%2C%20V.%2C%20Mattei%2C%20J.-P.%2C%20Bernard%2C%20M.%2C%20Guye%2C%20M.%2C%20Chabrand%2C%20P.%2C%20Champsaur%2C%20P.%20and%20Bendahan%2C%20D.%20%282020%29%20%26%23x201C%3BAssessment%20of%20proximal%20femur%20microarchitecture%20using%20ultra-high%20field%20MRI%20at%207%20Tesla%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BDiagnostic%20and%20Interventional%20Imaging%26lt%3B%5C%2Fi%26gt%3B%2C%20101%281%29%2C%20pp.%2045%26%23x2013%3B53.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.diii.2019.06.013%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.diii.2019.06.013%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessment%20of%20proximal%20femur%20microarchitecture%20using%20ultra-high%20field%20MRI%20at%207%20Tesla%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Guenoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Pithioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20-C.%22%2C%22lastName%22%3A%22Souplet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Le%20Corroller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Four%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Pauly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20-P.%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Chabrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Champsaur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22Purpose%5CnThe%20purpose%20of%20this%20study%20was%20to%20investigate%20bone%20microarchitecture%20of%20cadaveric%20proximal%20femurs%20using%20ultra-high%20field%20%28UHF%29%207-Tesla%20magnetic%20resonance%20imaging%20%28MRI%29%20and%20to%20compare%20the%20corresponding%20metrics%20with%20failure%20load%20assessed%20during%20mechanical%20compression%20test%20and%20areal%20bone%20mineral%20density%20%28ABMD%29%20measured%20using%20dual-energy%20X-ray%20absorptiometry.%5CnMaterials%20and%20methods%5CnABMD%20of%20ten%20proximal%20femurs%20from%20five%20cadavers%20%285%20women%3B%20mean%20age%3D86.2%5Cu00b13.8%20%28SD%29%20years%3B%20range%3A%2082.5%5Cu201390%20years%29%20were%20investigated%20using%20dual-energy%20X-ray%20absorptiometry%20and%20the%20bone%20volume%20fraction%2C%20trabecular%20thickness%2C%20trabecular%20spacing%2C%20fractal%20dimension%2C%20Euler%20characteristics%2C%20connectivity%20density%20and%20degree%20of%20anisotropy%20of%20each%20femur%20was%20quantified%20using%20UHF%20MRI.%20The%20whole%20set%20of%20specimens%20underwent%20mechanical%20compression%20tests%20to%20failure.%20The%20inter-rater%20reliability%20of%20microarchitecture%20characterization%20was%20assessed%20with%20the%20intraclass%20correlation%20coefficient%20%28ICC%29.%20Associations%20were%20searched%20using%20correlation%20tests%20and%20multiple%20regression%20analysis.%5CnResults%5CnThe%20inter-rater%20reliability%20for%20bone%20microarchitecture%20parameters%20measurement%20was%20good%20with%20ICC%20ranging%20from%200.80%20and%200.91.%20ABMD%20and%20the%20whole%20set%20of%20microarchitecture%20metrics%20but%20connectivity%20density%20significantly%20correlated%20with%20failure%20load.%20Microarchitecture%20metrics%20correlated%20to%20each%20other%20but%20did%20not%20correlate%20with%20ABMD.%20Multiple%20regression%20analysis%20disclosed%20that%20the%20combination%20of%20microarchitecture%20metrics%20and%20ABMD%20improved%20the%20association%20with%20failure%20load.%5CnConclusion%5CnFemur%20bone%20microarchitecture%20metrics%20quantified%20using%20UHF%20MRI%20significantly%20correlated%20with%20biomechanical%20parameters.%20The%20multimodal%20assessment%20of%20ABMD%20and%20trabecular%20bone%20microarchitecture%20using%20UHF%20MRI%20provides%20more%20information%20about%20fracture%20risk%20of%20femoral%20bone%20and%20might%20be%20of%20interest%20for%20future%20investigations%20of%20patients%20with%20undetected%20osteoporosis.%22%2C%22date%22%3A%22January%201%2C%202020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.diii.2019.06.013%22%2C%22ISSN%22%3A%222211-5684%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS2211568419301676%22%2C%22collections%22%3A%5B%225Z6CVJGB%22%2C%22NW6SZQBR%22%2C%226M38MJ3E%22%2C%226BEMAGEW%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-07-07T13%3A27%3A18Z%22%7D%7D%2C%7B%22key%22%3A%227Z8AKXLC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cammilleri%20et%20al.%22%2C%22parsedDate%22%3A%222019-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCammilleri%2C%20S.%2C%20Gabriel%2C%20S.%2C%20Le%20Troter%2C%20A.%2C%20Chagnaud%2C%20C.%2C%20Mattei%2C%20J.P.%2C%20Bendahan%2C%20D.%20and%20Guis%2C%20S.%20%282019%29%20%26%23x201C%3BKnee%20psoriatic%20enthesitis%20assessed%20using%20positron%20emission%20tomography%20%28PET%29%20-%20FNa%20merged%20to%20ultrahigh%20field%20magnetic%20resonance%20imaging%20%28UHF-MRI%29%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%20Bone%20Spine%26lt%3B%5C%2Fi%26gt%3B%2C%2086%283%29%2C%20pp.%20387%26%23x2013%3B388.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2019.01.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2019.01.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Knee%20psoriatic%20enthesitis%20assessed%20using%20positron%20emission%20tomography%20%28PET%29%20-%20FNa%20merged%20to%20ultrahigh%20field%20magnetic%20resonance%20imaging%20%28UHF-MRI%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Cammilleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Gabriel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Le%20Troter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22MAY%202019%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2019.01.002%22%2C%22ISSN%22%3A%221297-319X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%226BEMAGEW%22%2C%225P5FWCR9%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A30Z%22%7D%7D%2C%7B%22key%22%3A%228N7Y5I25%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Gossec%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGossec%2C%20L.%2C%20Soubrier%2C%20M.%2C%20Foissac%2C%20F.%2C%20Molto%2C%20A.%2C%20Richette%2C%20P.%2C%20Beauvais%2C%20C.%2C%20Ruyssen-Witrand%2C%20A.%2C%20Perdriger%2C%20A.%2C%20Chary-Valckenaere%2C%20I.%2C%20Mouterde%2C%20G.%2C%20Dernis%2C%20E.%2C%20Euller-Ziegler%2C%20L.%2C%20Flipo%2C%20R.-M.%2C%20Gilson%2C%20M.%2C%20Guis%2C%20S.%2C%20Mariette%2C%20X.%2C%20Pouplin%2C%20S.%2C%20Marhadour%2C%20T.%2C%20Schaeverbeke%2C%20T.%2C%20Sordet%2C%20C.%2C%20Fayet%2C%20F.%20and%20Dougados%2C%20M.%20%282019%29%20%26%23x201C%3BScreening%20for%20and%20management%20of%20comorbidities%20after%20a%20nurse-led%20program%3A%20results%20of%20a%203-year%20longitudinal%20study%20in%20769%20established%20rheumatoid%20arthritis%20patients%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BRMD%20open%26lt%3B%5C%2Fi%26gt%3B%2C%205%282%29%2C%20p.%20e000914.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Frmdopen-2019-000914%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Frmdopen-2019-000914%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Screening%20for%20and%20management%20of%20comorbidities%20after%20a%20nurse-led%20program%3A%20results%20of%20a%203-year%20longitudinal%20study%20in%20769%20established%20rheumatoid%20arthritis%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gossec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Soubrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frantz%22%2C%22lastName%22%3A%22Foissac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Molto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Richette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Beauvais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Ruyssen-Witrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aleth%22%2C%22lastName%22%3A%22Perdriger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Chary-Valckenaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gael%22%2C%22lastName%22%3A%22Mouterde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuelle%22%2C%22lastName%22%3A%22Dernis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liana%22%2C%22lastName%22%3A%22Euller-Ziegler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ren%5Cu00e9-Marc%22%2C%22lastName%22%3A%22Flipo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Gilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Mariette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Pouplin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Marhadour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Schaeverbeke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Sordet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Fayet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Dougados%22%7D%5D%2C%22abstractNote%22%3A%22Background%5C%2Fpurpose%3A%20Cardiovascular%20%28CV%29%20risk%2C%20cancer%2C%20infections%20and%20osteoporosis%20should%20be%20screened%20for%20in%20rheumatoid%20arthritis%20%28RA%29.%20The%20objective%20was%20to%20assess%203-year%20effects%20of%20a%20nurse%20visit%20for%20comorbidity%20counselling.%5CnMethods%3A%20This%20was%20an%20open%20long-term%20%283%20years%29%20extension%20of%20the%20Comorbidities%20and%20Education%20in%20Rheumatoid%20Arthritis%206-month%20randomised%20controlled%20trial%20in%20which%20patients%20with%20definite%2C%20stable%20RA%20were%20visiting%20a%20nurse%20for%20comorbidity%20counselling.%20Comorbidity%20status%20was%20assessed%20and%20nurses%20provided%20advice%20on%20screening%20and%20management%2C%20at%20baseline%20and%203%20years%20later.%20A%20score%20was%20developed%20to%20quantify%20comorbidity%20screening%20and%20management%3A%200-100%2C%20where%20lower%20scores%20indicate%20better%20screening%20and%20management.%20The%20score%20was%20compared%20between%20baseline%20and%203-year%20assessment%20using%20a%20Wilcoxon%20test%20for%20paired%20data.%5CnResults%3A%20Of%20the%20970%20recruited%20patients%2C%20776%20%2880%25%29%20were%20followed-up%20at%202-4%20years%20and%20769%20%2879%25%29%20had%20available%20data%20for%20comorbidities%20at%20both%20time%20points%3A%20mean%20%28%5Cu00b1SD%29%20age%2058%20%28%5Cu00b111%29%20years%20and%20mean%20disease%20duration%2014%20%28%5Cu00b110%29%20years%3B%20614%20%2880%25%29%20were%20women%2C%20the%20mean%20Disease%20Activity%20Score%2028%20was%203.0%5Cu00b11.3%2C%5Cu2009and%20538%20%2870%25%29%20were%20receiving%20a%20biologic.%20At%20baseline%2C%20the%20mean%20comorbidity%20screening%20score%20was%2036.6%20%28%5Cu00b119.9%29%20and%20it%20improved%20at%203%20years%20to%2024.3%20%28%5Cu00b117.8%29%20%28p%26lt%3B0.0001%29%2C%20thus%20with%20a%20relative%20improvement%20of%2033%25%20%28improvement%20of%2012%20points%29.%20CV%20risk%20screening%2C%20vaccination%20status%20and%20bone%20densitometry%20performance%20improved%20the%20most.%5CnConclusions%3A%20Comorbidity%20screening%20was%20suboptimal%20but%20improved%20notably%20over%203%20years%2C%20after%20a%20nurse-led%20programme%20aiming%20at%20checking%20systematically%20for%20comorbidity%20screening%20and%20giving%20patient%20advice.%20This%20long-term%20efficacy%20pleads%20in%20favour%20of%20nurse-led%20interventions%20to%20better%20address%20comorbidities%20in%20RA.%5CnTrial%20registration%20number%3A%20NCT01315652.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Frmdopen-2019-000914%22%2C%22ISSN%22%3A%222056-5933%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A40%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22D67JS36Q%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Benzaquen%20et%20al.%22%2C%22parsedDate%22%3A%222018-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBenzaquen%2C%20M.%2C%20Flachaire%2C%20B.%2C%20Rouby%2C%20F.%2C%20Berbis%2C%20P.%20and%20Guis%2C%20S.%20%282018%29%20%26%23x201C%3BParadoxical%20pustular%20psoriasis%20induced%20by%20ustekinumab%20in%20a%20patient%20with%20Crohn%26%23x2019%3Bs%20disease-associated%20spondyloarthropathy%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BRheumatology%20International%26lt%3B%5C%2Fi%26gt%3B%2C%2038%287%29%2C%20pp.%201297%26%23x2013%3B1299.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00296-018-4034-0%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00296-018-4034-0%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Paradoxical%20pustular%20psoriasis%20induced%20by%20ustekinumab%20in%20a%20patient%20with%20Crohn%27s%20disease-associated%20spondyloarthropathy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Benzaquen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Flachaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Rouby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Berbis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22Palmoplantar%20pustular%20psoriasis%20%28PPP%29%20is%20a%20clinical%20form%20of%20psoriasis%2C%20for%20which%20tumor%20necrosis%20factor%20alpha%20inhibitors%20%28TNFi%29%20or%20interleukins%2012%5C%2F23%20inhibitor%20%28ustekinumab%29%20can%20be%20a%20therapeutic%20option.%20Paradoxical%20psoriatic%20reactions%20induced%20by%20TNFi%20are%20now%20well%20known.%20We%20present%20the%20exceptional%20case%20of%20a%20paradoxical%20PPP%20appeared%20under%20ustekinumab%20in%20a%20patient%20with%20Crohn%26%23039%3Bs%20disease-associated%20spondyloarthropathy.%20A%2058-year-old%20woman%20presented%20with%20recent%20peripheral%20inflammatory%20arthralgias%20appeared%20in%20the%20context%20of%20a%20Crohn%26%23039%3Bs%20disease%20diagnosed%20in%202008.%20Three%20weeks%20after%20the%20first%20injection%20of%20ustekinumab%20390%5Cu00a0mg%20for%20a%20refractory%20Crohn%26%23039%3Bs%20disease%2C%20a%20slight%20pruritic%20erythematous%20and%20pustular%20dermatosis%20appeared%20on%20the%20right%20hand%20palm.%20The%20clinical%20aspect%20was%20strongly%20in%20favor%20of%20a%20PPP.%20Ustekinumab%20was%20discontinued%20and%20replaced%20by%20golimumab%2C%20leading%20to%20a%20complete%20healing%20of%20PPP%20after%2015%5Cu00a0days%20of%20discontinuation.%20Causality%20assessment%20calculated%20using%20the%20French%20method%20was%20plausible%20for%20ustekinumab%20in%20the%20induction%20of%20PPP.%20It%20was%20based%20on%20a%20compatible%20chronology%20according%20to%20time%20to%20onset%20associated%20with%20complete%20recovery%202%5Cu00a0weeks%20after%20cessation%20of%20treatment%2C%20and%20on%20the%20negative%20assessment%20of%20an%20alternative%20etiology%20%28nor%20bacterial%20or%20viral%20infection%2C%20nor%20other%20treatment%20taken%20by%20the%20patient%2C%20nor%20previous%20history%20of%20psoriasis%29.%20The%20worsening%20of%20underlying%20psoriasis%20under%20ustekinumab%20through%20the%20appearance%20of%20generalized%20or%20palmoplantar%20pustules%20has%20already%20been%20reported%20in%20five%20cases.%20We%20describe%20to%20our%20knowledge%20the%20first%20case%20of%20paradoxical%20PPP%20under%20ustekinumab%20in%20a%20patient%20with%20no%20known%20underlying%20psoriasis.%22%2C%22date%22%3A%222018-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00296-018-4034-0%22%2C%22ISSN%22%3A%221437-160X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%2C%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22IC2CRB45%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guenoun%20et%20al.%22%2C%22parsedDate%22%3A%222017-10-15%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuenoun%2C%20D.%2C%20Four%26%23xE9%3B%2C%20A.%2C%20Pithioux%2C%20M.%2C%20Guis%2C%20S.%2C%20Le%20Corroller%2C%20T.%2C%20Mattei%2C%20J.-P.%2C%20Pauly%2C%20V.%2C%20Guye%2C%20M.%2C%20Bernard%2C%20M.%2C%20Chabrand%2C%20P.%2C%20Champsaur%2C%20P.%20and%20Bendahan%2C%20D.%20%282017%29%20%26%23x201C%3BCorrelative%20Analysis%20of%20Vertebral%20Trabecular%20Bone%20Microarchitecture%20and%20Mechanical%20Properties%3A%20A%20Combined%20Ultra-high%20Field%20%287%20Tesla%29%20MRI%20and%20Biomechanical%20Investigation%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BSpine%26lt%3B%5C%2Fi%26gt%3B%2C%2042%2820%29%2C%20pp.%20E1165%26%23x2013%3BE1172.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FBRS.0000000000002163%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FBRS.0000000000002163%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correlative%20Analysis%20of%20Vertebral%20Trabecular%20Bone%20Microarchitecture%20and%20Mechanical%20Properties%3A%20A%20Combined%20Ultra-high%20Field%20%287%20Tesla%29%20MRI%20and%20Biomechanical%20Investigation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daphne%22%2C%22lastName%22%3A%22Guenoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Four%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Pithioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Le%20Corroller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Pauly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Chabrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Champsaur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22STUDY%20DESIGN%3A%20High-resolution%20imaging%20and%20biomechanical%20investigation%20of%20ex-vivo%20vertebrae.%5CnOBJECTIVE%3A%20The%20aim%20of%20this%20study%20was%20to%20assess%20bone%20microarchitecture%20of%20cadaveric%20vertebrae%20using%20ultra-high%20field%20%28UHF%29%207%20Tesla%20magnetic%20resonance%20imaging%20%28MRI%29%20and%20to%20determine%20whether%20the%20corresponding%20microarchitecture%20parameters%20were%20related%20to%20bone%20mineral%20density%20%28BMD%29%20and%20bone%20strength%20assessed%20by%20dual-energy%20x-ray%20absorptiometry%20%28DXA%29%20and%20mechanical%20compression%20tests.%5CnSUMMARY%20OF%20BACKGROUND%20DATA%3A%20Limitations%20of%20DXA%20for%20the%20assessment%20of%20bone%20fragility%20and%20osteoporosis%20have%20been%20recognized%20and%20criteria%20of%20microarchitecture%20alteration%20have%20been%20included%20in%20the%20definition%20of%20osteoporosis.%20Although%20vertebral%20fracture%20is%20the%20most%20common%20osteoporotic%20fracture%2C%20no%20study%20has%20assessed%20directly%20vertebral%20trabecular%20bone%20microarchitecture.%5CnMETHODS%3A%20BMD%20of%2024%20vertebrae%20%28L2%2C%20L3%2C%20L4%29%20from%20eight%20cadavers%20was%20investigated%20using%20DXA.%20The%20bone%20volume%20fraction%20%28BVF%29%2C%20trabecular%20thickness%20%28Tb.Th%29%2C%20and%20trabecular%20spacing%20%28Tb.Sp%29%20of%20each%20vertebra%20were%20quantified%20using%20UHF%20MRI.%20Measurements%20were%20performed%20by%20two%20operators%20to%20characterize%20the%20inter-rater%20reliability.%20The%20whole%20set%20of%20specimens%20underwent%20mechanical%20compression%20tests%20to%20failure%20and%20the%20corresponding%20failure%20stress%20was%20calculated.%5CnRESULTS%3A%20The%20inter-rater%20reliability%20for%20bone%20microarchitecture%20parameters%20was%20good%20with%20intraclass%20correlation%20coefficients%20ranging%20from%200.82%20to%200.94.%20Failure%20load%20and%20stress%20were%20significantly%20correlated%20with%20BVF%2C%20Tb.Sp%2C%20and%20BMD%20%28P%5Cu200a%26lt%3B%5Cu200a0.05%29.%20Tb.Th%20was%20only%20correlated%20with%20the%20failure%20stress%20%28P%5Cu200a%26lt%3B%5Cu200a0.05%29.%20Multiple%20regression%20analysis%20demonstrated%20that%20the%20combination%20of%20BVF%20and%20BMD%20improved%20the%20prediction%20of%20the%20failure%20stress%20from%20an%20adjusted%20R%5Cu200a%3D%5Cu200a0.384%20for%20BMD%20alone%20to%20an%20adjusted%20R%5Cu200a%3D%5Cu200a0.414.%5CnCONCLUSION%3A%20We%20demonstrated%20for%20the%20first%20time%20that%20the%20vertebral%20bone%20microarchitecture%20assessed%20with%20UHF%20MRI%20was%20significantly%20correlated%20with%20biomechanical%20parameters.%20Our%20data%20suggest%20that%20the%20multimodal%20assessment%20of%20BMD%20and%20trabecular%20bone%20microarchitecture%20with%20UHF%20MRI%20provides%20additional%20information%20on%20the%20risk%20of%20vertebral%20bone%20fracture%20and%20might%20be%20of%20interest%20for%20the%20future%20investigation%20of%20selected%20osteoporotic%20patients.%5CnLEVEL%20OF%20EVIDENCE%3A%20N%20%5C%2FA.%22%2C%22date%22%3A%22Oct%2015%2C%202017%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FBRS.0000000000002163%22%2C%22ISSN%22%3A%221528-1159%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%225Z6CVJGB%22%2C%22NW6SZQBR%22%2C%226M38MJ3E%22%2C%226BEMAGEW%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-07-07T13%3A27%3A17Z%22%7D%7D%2C%7B%22key%22%3A%224UXR6SLQ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Balandraud%20et%20al.%22%2C%22parsedDate%22%3A%222017%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBalandraud%2C%20N.%2C%20Texier%2C%20G.%2C%20Massy%2C%20E.%2C%20Muis-Pistor%2C%20O.%2C%20Martin%2C%20M.%2C%20Auger%2C%20I.%2C%20Guzian%2C%20M.-C.%2C%20Guis%2C%20S.%2C%20Pham%2C%20T.%20and%20Roudier%2C%20J.%20%282017%29%20%26%23x201C%3BLong%20term%20treatment%20with%20abatacept%20or%20tocilizumab%20does%20not%20increase%20Epstein-Barr%20virus%20load%20in%20patients%20with%20rheumatoid%20arthritis%20-%20A%20three%20years%20retrospective%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BPloS%20One%26lt%3B%5C%2Fi%26gt%3B%2C%2012%282%29%2C%20p.%20e0171623.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0171623%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0171623%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long%20term%20treatment%20with%20abatacept%20or%20tocilizumab%20does%20not%20increase%20Epstein-Barr%20virus%20load%20in%20patients%20with%20rheumatoid%20arthritis%20-%20A%20three%20years%20retrospective%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Texier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Massy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Muis-Pistor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marielle%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Caroline%22%2C%22lastName%22%3A%22Guzian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thao%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Epstein-Barr%20Virus%20%28EBV%29%20is%20a%20widely%20disseminated%20lymphotropic%20herpes%20virus%20implicated%20in%20benign%20and%20malignant%20disorders.%20In%20transplant%20patients%2C%20immunosuppressive%20drugs%20%28cyclosporine%29%20diminish%20control%20of%20EBV%20replication%2C%20potentially%20leading%20to%20lymphoproliferative%20disorders%20%28LPD%29.%20Rheumatoid%20arthritis%20%28RA%29%20patients%20have%20impaired%20control%20of%20EBV%20infection%20and%20have%20EBV%20load%20ten%20times%20higher%20than%20controls.%20As%20post%20transplant%20patients%2C%20patients%20with%20RA%20have%20increased%20risk%20of%20developing%20lymphomas.%20Immunosuppressive%20drugs%20used%20to%20treat%20RA%20%28conventional%20disease%20modifying%20drugs%20cDMARDs%20or%20biologics%20bDMARDs%29%20could%20enhance%20the%20risk%20of%20developing%20LPD%20in%20RA%20patients.%20We%20have%20previously%20shown%20that%20long%20term%20treatment%20with%20Methotrexate%20and%5C%2For%20TNF%20alpha%20antagonists%20does%20not%20increase%20EBV%20load%20in%20RA.%20Our%20objective%20was%20to%20monitor%20the%20Epstein-Barr%20Virus%20load%20in%20RA%20patients%20treated%20with%20Abatacept%20%28CTLA4%20Ig%29%2C%20a%20T%20cell%20coactivation%20inhibitor%2C%20and%20Tocilizumab%2C%20an%20anti%20IL6%20receptor%20antibody.%5CnMETHODS%3A%20EBV%20load%20in%20the%20peripheral%20blood%20mononuclear%20cells%20%28PBMCs%29%20of%2055%20patients%20under%20Abatacept%20%28in%2034%25%20associated%20with%20Methotrexate%29%20and%2035%20patients%20under%20Tocilizumab%20%28in%2037%25%20associated%20with%20Methotrexate%29%20was%20monitored%20for%20durations%20ranging%20from%206%20months%20to%203%20years%20by%20real%20time%20PCR.%20The%20influences%20of%20treatment%20duration%20and%20disease%20activity%20score%2028%20%28DAS28%29%20index%20on%20EBV%20load%20were%20analyzed.%5CnRESULTS%3A%20Abatacept%20did%20not%20significantly%20modify%20EBV%20load%20over%20time.%20Tocilizumab%20significantly%20diminished%20EBV%20load%20over%20time.%20No%20patient%20%28of%2090%29%20developed%20EBV%20associated%20lymphoma.%5CnCONCLUSION%3A%20Long%20term%20treatment%20with%20Abatacept%20or%20Tocilizumab%20does%20not%20increase%20EBV%20load%20in%20the%20PBMNCs%20of%20patients%20with%20RA.%22%2C%22date%22%3A%222017%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0171623%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-11-06T10%3A43%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22WL6VEA92%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Gottenberg%20et%20al.%22%2C%22parsedDate%22%3A%222016-09-20%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGottenberg%2C%20J.-E.%2C%20Brocq%2C%20O.%2C%20Perdriger%2C%20A.%2C%20Lassoued%2C%20S.%2C%20Berthelot%2C%20J.-M.%2C%20Wendling%2C%20D.%2C%20Euller-Ziegler%2C%20L.%2C%20Soubrier%2C%20M.%2C%20Richez%2C%20C.%2C%20Fautrel%2C%20B.%2C%20Constantin%2C%20A.L.%2C%20Mariette%2C%20X.%2C%20Morel%2C%20J.%2C%20Gilson%2C%20M.%2C%20Cormier%2C%20G.%2C%20Salmon%2C%20J.H.%2C%20Rist%2C%20S.%2C%20Liot%26%23xE9%3B%2C%20F.%2C%20Marotte%2C%20H.%2C%20Bonnet%2C%20C.%2C%20Marcelli%2C%20C.%2C%20Sellam%2C%20J.%2C%20Meyer%2C%20O.%2C%20Solau-Gervais%2C%20E.%2C%20Guis%2C%20S.%2C%20Ziza%2C%20J.-M.%2C%20Zarnitsky%2C%20C.%2C%20Chary-Valckenaere%2C%20I.%2C%20Vittecoq%2C%20O.%2C%20Saraux%2C%20A.%2C%20Pers%2C%20Y.-M.%2C%20Gayraud%2C%20M.%2C%20Bolla%2C%20G.%2C%20Claudepierre%2C%20P.%2C%20Ardizzone%2C%20M.%2C%20Dernis%2C%20E.%2C%20Breban%2C%20M.A.%2C%20Fain%2C%20O.%2C%20Balblanc%2C%20J.-C.%2C%20Aberkane%2C%20O.%2C%20Vazel%2C%20M.%2C%20Back%2C%20C.%2C%20Candon%2C%20S.%2C%20Chatenoud%2C%20L.%2C%20Perrodeau%2C%20E.%2C%20Sibilia%2C%20J.%20and%20Ravaud%2C%20P.%20%282016%29%20%26%23x201C%3BNon-TNF-Targeted%20Biologic%20vs%20a%20Second%20Anti-TNF%20Drug%20to%20Treat%20Rheumatoid%20Arthritis%20in%20Patients%20With%20Insufficient%20Response%20to%20a%20First%20Anti-TNF%20Drug%3A%20A%20Randomized%20Clinical%20Trial%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJAMA%26lt%3B%5C%2Fi%26gt%3B%2C%20316%2811%29%2C%20pp.%201172%26%23x2013%3B1180.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjama.2016.13512%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjama.2016.13512%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Non-TNF-Targeted%20Biologic%20vs%20a%20Second%20Anti-TNF%20Drug%20to%20Treat%20Rheumatoid%20Arthritis%20in%20Patients%20With%20Insufficient%20Response%20to%20a%20First%20Anti-TNF%20Drug%3A%20A%20Randomized%20Clinical%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques-Eric%22%2C%22lastName%22%3A%22Gottenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Brocq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aleth%22%2C%22lastName%22%3A%22Perdriger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Slim%22%2C%22lastName%22%3A%22Lassoued%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marie%22%2C%22lastName%22%3A%22Berthelot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Wendling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liana%22%2C%22lastName%22%3A%22Euller-Ziegler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Soubrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Richez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Fautrel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%20L.%22%2C%22lastName%22%3A%22Constantin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Mariette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22Gilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregoire%22%2C%22lastName%22%3A%22Cormier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Hugues%22%2C%22lastName%22%3A%22Salmon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Rist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Liot%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Marotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Marcelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremie%22%2C%22lastName%22%3A%22Sellam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Solau-Gervais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Ziza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Zarnitsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Chary-Valckenaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Vittecoq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Saraux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves-Marie%22%2C%22lastName%22%3A%22Pers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Gayraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Bolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Claudepierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Ardizzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Dernis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%20A.%22%2C%22lastName%22%3A%22Breban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Fain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Charles%22%2C%22lastName%22%3A%22Balblanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ouafaa%22%2C%22lastName%22%3A%22Aberkane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Vazel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Back%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Candon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucienne%22%2C%22lastName%22%3A%22Chatenoud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Perrodeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Sibilia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Ravaud%22%7D%5D%2C%22abstractNote%22%3A%22Importance%3A%20One-third%20of%20patients%20with%20rheumatoid%20arthritis%20show%20inadequate%20response%20to%20tumor%20necrosis%20factor%20%5Cu03b1%20%28TNF-%5Cu03b1%29%20inhibitors%3B%20little%20guidance%20on%20choosing%20the%20next%20treatment%20exists.%5CnObjective%3A%20To%20compare%20the%20efficacy%20of%20a%20non-TNF-targeted%20biologic%20%28non-TNF%29%20vs%20a%20second%20anti-TNF%20drug%20for%20patients%20with%20insufficient%20response%20to%20a%20TNF%20inhibitor.%5CnDesign%2C%20Setting%2C%20and%20Participants%3A%20A%20total%20of%20300%20patients%20%28conducted%20between%202009-2012%29%20with%20rheumatoid%20arthritis%2C%20with%20persistent%20disease%20activity%20%28disease%20activity%20score%20in%2028%20joints-erythrocyte%20sedimentation%20rate%20%5BDAS28-ESR%5D%20%5Cu2009%5Cu2265%5Cu20093.2%20%5Brange%2C%200-9.3%5D%29%20and%20an%20insufficient%20response%20to%20anti-TNF%20therapy%20were%20included%20in%20a%2052-week%20multicenter%2C%20pragmatic%2C%20open-label%20randomized%20clinical%20trial.%20The%20final%20follow-up%20date%20was%20in%20August%202013.%5CnInterventions%3A%20Patients%20were%20randomly%20assigned%20%281%3A1%29%20to%20receive%20a%20non-TNF-targeted%20biologic%20agent%20or%20an%20anti-TNF%20that%20differed%20from%20their%20previous%20treatment.%20The%20choice%20of%20the%20biologic%20prescribed%20within%20each%20randomized%20group%20was%20left%20to%20the%20treating%20clinician.%5CnMain%20Outcomes%20and%20Measures%3A%20The%20primary%20outcome%20was%20the%20proportion%20of%20patients%20with%20good%20or%20moderate%20response%20according%20to%20the%20European%20League%20Against%20Rheumatism%20%28EULAR%29%20scale%20at%20week%2024.%20Secondary%20outcomes%20included%20the%20EULAR%20response%20at%20weeks%2012%20and%2052%3B%20at%20weeks%2012%2C%2024%2C%20and%2052%3B%20DAS28ESR%2C%20low%20disease%20activity%20%28DAS28%20%5Cu22643.2%29%2C%20remission%20%28DAS28%20%5Cu22642.6%29%3B%20serious%20adverse%20events%3B%20and%20serious%20infections.%5CnResults%3A%20Of%20the%20300%20randomized%20patients%20%28243%20%5B83.2%25%5D%20women%3B%20mean%20%5BSD%5D%20age%2C%2057.1%20%5B12.2%5D%20years%3B%20baseline%20DAS28-ESR%2C%205.1%20%5B1.1%5D%29%2C%20269%20%2889.7%25%29%20completed%20the%20study.%20At%20week%2024%2C%20101%20of%20146%20patients%20%2869%25%29%20in%20the%20non-TNF%20group%20and%2076%20%2852%25%29%20in%20the%20second%20anti-TNF%20group%20achieved%20a%20good%20or%20moderate%20EULAR%20response%20%28OR%2C%202.06%3B%2095%25%20CI%2C%201.27-3.37%3B%20P%5Cu2009%3D%5Cu2009.004%2C%20with%20imputation%20of%20missing%20data%3B%20absolute%20difference%2C%2017.2%25%3B%2095%25%20CI%2C%206.2%25%20to%2028.2%25%29.%20The%20DAS28-ESR%20was%20lower%20in%20the%20non-TNF%20group%20than%20in%20the%20second%20anti-TNF%20group%20%28mean%20difference%20adjusted%20for%20baseline%20differences%2C%20-0.43%3B%2095%25%20CI%2C%20-0.72%20to%20-0.14%3B%20P%5Cu2009%3D%5Cu2009.004%29.%20At%20weeks%2024%20and%2052%2C%20more%20patients%20in%20the%20non-TNF%20group%20vs%20the%20second%20anti-TNF%20group%20showed%20low%20disease%20activity%20%2845%25%20vs%2028%25%20at%20week%2024%3B%20OR%2C%202.09%3B%2095%25%20CI%2C%201.27%20to%203.43%3B%20P%5Cu2009%3D%5Cu2009.004%20and%2041%25%20vs%2023%25%20at%20week%2052%3B%20OR%2C%202.26%3B%2095%25%20CI%2C%201.33%20to%203.86%3B%20P%5Cu2009%3D%5Cu2009.003%29.%5CnConclusions%20and%20Relevance%3A%20Among%20patients%20with%20rheumatoid%20arthritis%20previously%20treated%20with%20anti-TNF%20drugs%20but%20with%20inadequate%20primary%20response%2C%20a%20non-TNF%20biologic%20agent%20was%20more%20effective%20in%20achieving%20a%20good%20or%20moderate%20disease%20activity%20response%20at%2024%20weeks%20than%20was%20the%20second%20anti-TNF%20medication.%5CnTrial%20Registration%3A%20clinicaltrials.gov%20Identifier%3A%20NCT01000441.%22%2C%22date%22%3A%222016-09-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjama.2016.13512%22%2C%22ISSN%22%3A%221538-3598%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A40%3A51Z%22%7D%7D%2C%7B%22key%22%3A%225RTGM6HB%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mege%20et%20al.%22%2C%22parsedDate%22%3A%222016-08%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMege%2C%20D.%2C%20Cammilleri%2C%20S.%2C%20Mundler%2C%20O.%2C%20Dignat-George%2C%20F.%2C%20Dubois%2C%20C.%2C%20Panicot-Dubois%2C%20L.%20and%20Guis%2C%20S.%20%282016%29%20%26%23x201C%3BCirculating%20microparticles%20bearing%20Fibrin%20associated%20with%20whole-body%2018FDG-PET%3A%20diagnostic%20tools%20to%20detect%20paraneoplastic%20polymyalgia%20rheumatica%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BRheumatology%20International%26lt%3B%5C%2Fi%26gt%3B%2C%2036%288%29%2C%20pp.%201099%26%23x2013%3B1103.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00296-016-3510-7%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00296-016-3510-7%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Circulating%20microparticles%20bearing%20Fibrin%20associated%20with%20whole-body%2018FDG-PET%3A%20diagnostic%20tools%20to%20detect%20paraneoplastic%20polymyalgia%20rheumatica%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Mege%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Cammilleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Mundler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Dignat-George%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Panicot-Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22Polymyalgia%20rheumatica%20%28PMR%29%2C%20a%20chronic%20inflammatory%20rheumatism%2C%20can%20be%20the%20expression%20of%20a%20paraneoplastic%20syndrome.%20The%20same%20clinical%20symptoms%20are%20frequently%20observed%20at%20the%20early%20stage%20of%20the%20benign%20and%20malignant%20forms.%20Here%2C%20our%20aim%20was%20to%20develop%20diagnostic%20tools%20to%20differentiate%20paraneoplastic%20PMR%20from%20essential%20PMR.%20We%20combined%20an%2018FDG-PET%20and%20detection%20of%20circulating%20procoagulant%20microparticles%20%28MPs%29%2C%20such%20as%20fibrin%20positive%20%28FibMPs%29%2C%20by%20flow%20cytometry.%20Two%20patients%20with%20PMR%20and%20a%20similar%20profile%20were%20selected.%20In%20the%20two%20patients%2C%20the%2018FDG-PET%20revealed%20a%20hypermetabolic%20focus.%20However%2C%20the%20concentrations%20of%20fibrin%2B%5C%2Fannexin%2B%20microparticles%20detected%20were%20%2810%20times%20higher%20in%20one%20of%20the%20two%20patients%2C%20who%20was%20later%20found%20to%20have%20breast%20cancer.%20The%20association%20of%2018FDG-PET%20and%20the%20detection%20of%20microparticle%20fibrin%20positives%20by%20flow%20cytometry%20allows%20separating%20essential%20PMR%20%28hypermetabolism%20by%2018FDG-PET%2C%20low%20FibMPs%29%20from%20paraneoplastic%20PMR.%22%2C%22date%22%3A%22Aug%202016%22%2C%22language%22%3A%22ENG%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00296-016-3510-7%22%2C%22ISSN%22%3A%221437-160X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%2C%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22YX9WKGH7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Montoya%20et%20al.%22%2C%22parsedDate%22%3A%222016-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontoya%2C%20J.%2C%20Matta%2C%20N.B.%2C%20Suchon%2C%20P.%2C%20Guzian%2C%20M.C.%2C%20Lambert%2C%20N.C.%2C%20Mattei%2C%20J.P.%2C%20Guis%2C%20S.%2C%20Breban%2C%20M.%2C%20Roudier%2C%20J.%20and%20Balandraud%2C%20N.%20%282016%29%20%26%23x201C%3BPatients%20with%20ankylosing%20spondylitis%20have%20been%20breast%20fed%20less%20often%20than%20healthy%20controls%3A%20a%20case-control%20retrospective%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20the%20Rheumatic%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2C%2075%285%29%2C%20pp.%20879%26%23x2013%3B882.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fannrheumdis-2015-208187%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fannrheumdis-2015-208187%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Patients%20with%20ankylosing%20spondylitis%20have%20been%20breast%20fed%20less%20often%20than%20healthy%20controls%3A%20a%20case-control%20retrospective%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Montoya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20B.%22%2C%22lastName%22%3A%22Matta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Suchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Guzian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20C.%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Breban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Balandraud%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Ankylosing%20spondylitis%20%28AS%29%20is%20a%20chronic%20inflammatory%20disease%20affecting%20the%20spine%20and%20pelvis%20of%20young%20adults.%20On%20the%20HLA-B27%20genetic%20background%2C%20the%20occurrence%20of%20AS%20is%20influenced%20by%20the%20intestinal%20microbiota.%20The%20goal%20of%20our%20study%20was%20to%20test%20whether%20breast%20feeding%2C%20which%20influences%20microbiota%2C%20can%20prevent%20the%20development%20of%20AS.%5CnMETHODS%3A%20First%2C%20203%20patients%20with%20HLA-B27-positive%20AS%20fulfilling%20the%20modified%20New%20York%20criteria%20were%20recruited%20in%20the%20Department%20of%20Rheumatology%2C%20Ste%20Marguerite%20hospital%20in%20Marseilles.%20A%20total%20of%20293%20healthy%20siblings%20were%20also%20recruited%20to%20make%20up%20a%20control%20group%20within%20the%20same%20families.%20Second%2C%20280%20healthy%20controls%2C%20and%20100%20patients%20with%20rheumatoid%20arthritis%20and%20their%20siblings%20were%20recruited.%20The%20data%20collected%20were%20age%2C%20gender%2C%20number%20of%20brothers%20and%20sisters%2C%20age%20at%20disease%20onset%2C%20type%20and%20duration%20of%20feeding%20%28breast%20or%20bottle%29.%5CnRESULTS%3A%20Patients%20with%20AS%20had%20been%20breast%20fed%20less%20often%20than%20healthy%20controls.%20In%20families%20where%20children%20were%20breast%20fed%2C%20the%20patients%20with%20AS%20were%20less%20often%20breast%20fed%20than%20their%20healthy%20siblings%20%2857%25%20vs%2072%25%29%2C%20giving%20an%20OR%20for%20AS%20onset%20of%200.53%20%2895%25%20CI%20%280.36%20to%200.77%29%2C%20p%20value%3D0.0009%29.%20Breast%20feeding%20reduced%20familial%20prevalence%20of%20AS.%20The%20frequency%20of%20breast%20feeding%20was%20similar%20in%20the%20AS%20siblings%20and%20in%20the%20280%20unrelated%20controls.%20However%2C%20patients%20with%20AS%20were%20less%20often%20breast%20fed%20compared%20with%20the%20280%20unrelated%20controls%20%28OR%200.6%2C%2095%25%20CI%20%280.42%20to%200.89%29%2C%20p%26lt%3B0.01%29.%5CnCONCLUSIONS%3A%20Our%20study%20suggests%20a%20breastfeeding-induced%20protective%20effect%20on%20the%20occurrence%20of%20AS.%20To%20our%20knowledge%2C%20this%20is%20the%20first%20study%20of%20breastfeeding%20history%20in%20patients%20with%20AS.%22%2C%22date%22%3A%222016-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fannrheumdis-2015-208187%22%2C%22ISSN%22%3A%221468-2060%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222022-01-26T19%3A46%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22TAM3984G%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guis%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuis%2C%20S.%2C%20Berbis%2C%20P.%2C%20Stephan%2C%20D.%2C%20Bertin%2C%20D.%2C%20Amatore%2C%20F.%2C%20Balandraud%2C%20N.%2C%20Lesavre%2C%20N.%20and%20Desplat-J%26%23xE9%3Bgo%2C%20S.%20%282016%29%20%26%23x201C%3BTWEAK-binding%20autoantibodies%20are%20generated%20during%20psoriatic%20arthritis%20and%20are%20not%20influenced%20by%20anti-TNF%20therapy%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Translational%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%2014%281%29%2C%20p.%20185.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12967-016-0923-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12967-016-0923-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22TWEAK-binding%20autoantibodies%20are%20generated%20during%20psoriatic%20arthritis%20and%20are%20not%20influenced%20by%20anti-TNF%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Berbis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Stephan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Bertin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Amatore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Lesavre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Desplat-J%5Cu00e9go%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20TNF%20weakly%20inducer%20of%20apoptosis%20%28TWEAK%29%20is%20member%20of%20the%20TNF%20ligand%20superfamily.%20Various%20data%20support%20that%20TWEAK%20produced%20by%20synovial%20macrophages%20may%20contribute%20to%20synovitis%20observed%20in%20psoriatic%20arthritis%20%28PsoA%29.%20In%20PsoA%2C%20anti-TNF%20therapy%20has%20been%20successful%20in%20agreement%20with%20the%20key%20role%20of%20TNF%20in%20the%20pathogenesis%20and%20the%20generation%20by%20PsoA%20patients%20of%20anti-TNF%20autoantibodies%20referred%20as%20%26quot%3Bbeneficial%20autoimmunity%20to%20pro-inflammatory%20mediators%26quot%3B.%20However%2C%20the%20role%20of%20TNF-alpha%20in%20the%20regulation%20of%20TWEAK%20modulation%20of%20inflammation%20during%20PsoA%20remains%20unknown.%5CnMETHODS%3A%20We%20have%20studied%20level%20course%20during%20anti-TNF%20therapy%20of%20serum%20soluble%20TWEAK.%20In%20the%20same%20cohort%2C%20we%20have%20investigated%20the%20generation%20of%20TWEAK-binding%20autoantibodies%20by%20PsoA%20patients%20before%20and%20after%20anti-TNF%20therapy.%5CnRESULTS%3A%20Patients%20with%20PsoA%20had%20significantly%20higher%20serum%20levels%20of%20TWEAK%20compared%20with%20controls%20%5Brespective%20means%20%28%5Cu00b1SEM%29%20were%20645%5Cu00a0pg%5C%2Fml%20%2864%29%20and%20467%5Cu00a0pg%5C%2Fml%20%2823%29%3B%20%28p%5Cu00a0%3D%5Cu00a00.006%29%5D%20but%20serum%20soluble%20TWEAK%20levels%20were%20not%20correlated%20with%20BASDAI%20%28Spearman%26%23039%3Bs%20coefficients%20%26lt%3B0.003%2C%20p%5Cu00a0%26gt%3B%5Cu00a00.05%29.%20Our%20study%20showed%20that%20soluble%20TWEAK%20levels%20were%20not%20modulated%20by%20etanercept%20therapy%20%5Brespective%20Means%20%28%5Cu00b1SEM%29%20were%20605%20%2895%29%20%28week%2012%29%20and%20744%20%2897%29%20%28week%2024%29%20pg%5C%2Fml%3B%20%28p%5Cu00a0%26gt%3B%5Cu00a00.23%29%5D.%20Anti-TWEAK%20autoantibodies%20were%20detected%20in%209%5C%2F13%20%2869.2%5Cu00a0%25%29%20PsoA%20patients%20at%20inclusion%20and%20only%20in%203%5C%2F57%20%285.3%5Cu00a0%25%29%20healthy%20blood%20donors%20%28p%5Cu00a0%26lt%3B%5Cu00a00.0001%29.%20These%20circulating%20antibodies%20were%20persistent%20in%20PsoA%20patients%20and%20detected%20at%20similar%20levels%20during%20etanercept%20therapy.%20Moreover%20we%20showed%20that%20they%20had%20a%20down%20regulating%20effect%20on%20CCL-2%20secretion%20by%20endothelial%20cells%20stimulated%20by%20rh%20TWEAK%20in%20vitro.%5CnCONCLUSION%3A%20Our%20study%20revealed%20that%20during%20psoriatic%20arthritis%20%281%29%20serum%20TWEAK%20was%20up%20regulated%20and%20%282%29%20TWEAK-binding%20autoantibodies%20are%20generated.%20Both%20parameters%20were%20not%20influenced%20by%20anti-TNF%20therapy%20and%20persisted%20at%20high%20levels%20during%20anti-TNF%20therapy.%20For%20the%20first%20time%20we%20described%20here%20TWEAK-binding%20IgG%20autoantibodies%20with%20a%20down%20regulating%20effect%20on%20CCL-2%20secretion%20by%20endothelial%20cells%20stimulated%20by%20rh%20TWEAK%20in%20vitro.%20Finally%2C%20our%20results%20suggest%20that%20TWEAK%20may%20be%20involved%20in%20PsoA%20pathogeny.%20Trial%20registration%20This%20clinical%20trial%20was%20approved%20by%20the%20local%20Ethics%20Committee%20%26quot%3BComit%5Cu00e9%20de%20Protection%20des%20Personnes%20Sud-M%5Cu00e9diterran%5Cu00e9e%20V%26quot%3B%20with%20the%20registration%20number%3A%202011-002954-29%2C%20and%20French%20health%20minister%20registration%20number%20AFSSAPS%20A110784-42%20obtained%20the%2008%5C%2F22%5C%2F2011.%20This%20clinical%20trial%20is%20registered%20in%20Clinical%20trial.gov%20under%20the%20number%3A%20NCT02164214.%22%2C%22date%22%3A%222016%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12967-016-0923-8%22%2C%22ISSN%22%3A%221479-5876%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%2C%22LPVXE8S8%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22W528J5LM%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Zink%20et%20al.%22%2C%22parsedDate%22%3A%222015-09-18%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZink%2C%20J.-V.%2C%20Souteyrand%2C%20P.%2C%20Guis%2C%20S.%2C%20Chagnaud%2C%20C.%2C%20Fur%2C%20Y.L.%2C%20Militianu%2C%20D.%2C%20Mattei%2C%20J.-P.%2C%20Rozenbaum%2C%20M.%2C%20Rosner%2C%20I.%2C%20Guye%2C%20M.%2C%20Bernard%2C%20M.%20and%20Bendahan%2C%20D.%20%282015%29%20%26%23x201C%3BStandardized%20quantitative%20measurements%20of%20wrist%20cartilage%20in%20healthy%20humans%20using%203T%20magnetic%20resonance%20imaging%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BWorld%20Journal%20of%20Orthopedics%26lt%3B%5C%2Fi%26gt%3B%2C%206%288%29%2C%20pp.%20641%26%23x2013%3B648.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5312%5C%2Fwjo.v6.i8.641%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5312%5C%2Fwjo.v6.i8.641%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Standardized%20quantitative%20measurements%20of%20wrist%20cartilage%20in%20healthy%20humans%20using%203T%20magnetic%20resonance%20imaging%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Vincent%22%2C%22lastName%22%3A%22Zink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Souteyrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%20Le%22%2C%22lastName%22%3A%22Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Militianu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Rozenbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Itzhak%22%2C%22lastName%22%3A%22Rosner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22AIM%3A%20To%20quantify%20the%20wrist%20cartilage%20cross-sectional%20area%20in%20humans%20from%20a%203D%20magnetic%20resonance%20imaging%20%28MRI%29%20dataset%20and%20to%20assess%20the%20corresponding%20reproducibility.%5CnMETHODS%3A%20The%20study%20was%20conducted%20in%2014%20healthy%20volunteers%20%286%20females%20and%208%20males%29%20between%2030%20and%2058%20years%20old%20and%20devoid%20of%20articular%20pain.%20Subjects%20were%20asked%20to%20lie%20down%20in%20the%20supine%20position%20with%20the%20right%20hand%20positioned%20above%20the%20pelvic%20region%20on%20top%20of%20a%20home-built%20rigid%20platform%20attached%20to%20the%20scanner%20bed.%20The%20wrist%20was%20wrapped%20with%20a%20flexible%20surface%20coil.%20MRI%20investigations%20were%20performed%20at%203T%20%28Verio-Siemens%29%20using%20volume%20interpolated%20breath%20hold%20examination%20%28VIBE%29%20and%20dual%20echo%20steady%20state%20%28DESS%29%20MRI%20sequences.%20Cartilage%20cross%20sectional%20area%20%28CSA%29%20was%20measured%20on%20a%20slice%20of%20interest%20selected%20from%20a%203D%20dataset%20of%20the%20entire%20carpus%20and%20metacarpal-phalangeal%20areas%20on%20the%20basis%20of%20anatomical%20criteria%20using%20conventional%20image%20processing%20radiology%20software.%20Cartilage%20cross-sectional%20areas%20between%20opposite%20bones%20in%20the%20carpal%20region%20were%20manually%20selected%20and%20quantified%20using%20a%20thresholding%20method.%5CnRESULTS%3A%20Cartilage%20CSA%20measurements%20performed%20on%20a%20selected%20predefined%20slice%20were%20292.4%20%5Cu00b1%2039%20mm%282%29%20using%20the%20VIBE%20sequence%20and%20slightly%20lower%2C%20270.4%20%5Cu00b1%2050.6%20mm%282%29%2C%20with%20the%20DESS%20sequence.%20The%20inter%20%2814.1%25%29%20and%20intra%20%282.4%25%29%20subject%20variability%20was%20similar%20for%20both%20MRI%20methods.%20The%20coefficients%20of%20variation%20computed%20for%20the%20repeated%20measurements%20were%20also%20comparable%20for%20the%20VIBE%20%282.4%25%29%20and%20the%20DESS%20%284.8%25%29%20sequences.%20The%20carpus%20length%20averaged%20over%20the%20group%20was%2037.5%20%5Cu00b1%202.8%20mm%20with%20a%207.45%25%20between-subjects%20coefficient%20of%20variation.%20Of%20note%2C%20wrist%20cartilage%20CSA%20measured%20with%20either%20the%20VIBE%20or%20the%20DESS%20sequences%20was%20linearly%20related%20to%20the%20carpal%20bone%20length.%20The%20variability%20between%20subjects%20was%20significantly%20reduced%20to%208.4%25%20when%20the%20CSA%20was%20normalized%20with%20respect%20to%20the%20carpal%20bone%20length.%5CnCONCLUSION%3A%20The%20ratio%20between%20wrist%20cartilage%20CSA%20and%20carpal%20bone%20length%20is%20a%20highly%20reproducible%20standardized%20measurement%20which%20normalizes%20the%20natural%20diversity%20between%20individuals.%22%2C%22date%22%3A%222015-09-18%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.5312%5C%2Fwjo.v6.i8.641%22%2C%22ISSN%22%3A%222218-5836%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%5D%2C%22dateModified%22%3A%222023-06-26T07%3A49%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22QMEVP5GJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Silvy%20et%20al.%22%2C%22parsedDate%22%3A%222015%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSilvy%2C%20F.%2C%20Bertin%2C%20D.%2C%20Bardin%2C%20N.%2C%20Auger%2C%20I.%2C%20Guzian%2C%20M.-C.%2C%20Mattei%2C%20J.-P.%2C%20Guis%2C%20S.%2C%20Roudier%2C%20J.%20and%20Balandraud%2C%20N.%20%282015%29%20%26%23x201C%3BAntinuclear%20Antibodies%20in%20Patients%20with%20Psoriatic%20Arthritis%20Treated%20or%20Not%20with%20Biologics%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BPloS%20One%26lt%3B%5C%2Fi%26gt%3B%2C%2010%287%29%2C%20p.%20e0134218.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0134218%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0134218%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Antinuclear%20Antibodies%20in%20Patients%20with%20Psoriatic%20Arthritis%20Treated%20or%20Not%20with%20Biologics%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Silvy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Bertin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Bardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Caroline%22%2C%22lastName%22%3A%22Guzian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20With%20the%20emergence%20of%20biotherapies%2C%20accurate%20diagnosis%20in%20early%20arthritis%20is%20needed.%20At%20this%20time%2C%20there%20is%20no%20biological%20marker%20of%20psoriatic%20arthritis.%5CnOBJECTIVE%3A%20To%20test%20whether%20antinuclear%20antibodies%20%28ANA%29%20can%20be%20used%20as%20a%20diagnostic%20tool%20in%20psoriatic%20arthritis%20%28PsA%29%2C%20we%20evaluated%20the%20prevalence%20of%20ANA%20in%20biologic-na%5Cu00efve%20PsA%20patients%20and%20in%20healthy%20blood%20donors.%5CnMETHODS%3A%20232%20patients%20from%20the%20Rheumatology%20department%2C%20St%20Marguerite%26%23039%3Bs%20Hospital%2C%20Marseilles%2C%20who%20fulfilled%20the%20CASPAR%20criteria%20for%20PsA%2C%20underwent%20clinical%20and%20laboratory%20investigations.%20Antinuclear%20antibodies%20%28ANA%29%2C%20anti-extractable%20nuclear%20antigen%20antibodies%20%28ENA%29%2C%20rheumatoid%20factor%20%28RF%29%2C%20anti-citrullinated%20protein%20antibodies%20%28ACPA%29%20were%20assayed.%20Ninety-one%20healthy%20blood%20donors%20were%20also%20tested.%5CnRESULTS%3A%20Detection%20of%20ANA%20by%20indirect%20immunofluorescence%20was%20significantly%20more%20frequent%20in%20sera%20from%20PsA%20patients%20than%20those%20from%20controls%20at%20serum%20dilution%20of%201%3A100%20%2857%25%20compared%20with%2040%25%2C%20Odds%20Ratio%20%28OR%29%201.98%20%281.2-3.4%29%20p%26lt%3B0.02%29%20and%201%3A160%20%2852%25%20compared%20with%2024%25%2C%20OR%203%2C7%20%281.9-7.2%29%20p%26lt%3B0.001%29.%20No%20patients%20had%20lupus%20specific%20autoantibodies%2C%2015%20%25%20had%20RF%20%2834%5C%2F232%29%2C%20and%201.7%20%25%20had%20ACPA%20%284%5C%2F232%29.%5CnCONCLUSIONS%3A%20Detection%20of%20ANA%20was%20more%20frequent%20in%20sera%20from%20PsA%20patients%20than%20in%20those%20from%20healthy%20controls.%20This%20suggests%20that%20ANA%20could%20be%20a%20diagnosis%20orientation%20tool%20in%20PsA.%20Nevertheless%2C%20the%20specificity%20of%20these%20antibodies%20still%20remains%20to%20be%20investigated.%22%2C%22date%22%3A%222015%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0134218%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A37Z%22%7D%7D%2C%7B%22key%22%3A%228ZKX6Q8R%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cheung%20et%20al.%22%2C%22parsedDate%22%3A%222014-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCheung%2C%20P.P.%2C%20Dougados%2C%20M.%2C%20Andre%2C%20V.%2C%20Balandraud%2C%20N.%2C%20Chal%26%23xE8%3Bs%2C%20G.%2C%20Chary-Valckenaere%2C%20I.%2C%20Dernis%2C%20E.%2C%20Gill%2C%20G.%2C%20Gilson%2C%20M.%2C%20Guis%2C%20S.%2C%20Mouterde%2C%20G.%2C%20Pavy%2C%20S.%2C%20Pouyol%2C%20F.%2C%20Marhadour%2C%20T.%2C%20Richette%2C%20P.%2C%20Ruyssen-Witrand%2C%20A.%2C%20Soubrier%2C%20M.%2C%20Nguyen%2C%20M.%20and%20Gossec%2C%20L.%20%282014%29%20%26%23x201C%3BThe%20learning%20curve%20of%20nurses%20for%20the%20assessment%20of%20swollen%20and%20tender%20joints%20in%20rheumatoid%20arthritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%2C%20Bone%2C%20Spine%3A%20Revue%20Du%20Rhumatisme%26lt%3B%5C%2Fi%26gt%3B%2C%2081%282%29%2C%20pp.%20154%26%23x2013%3B159.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2013.06.006%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2013.06.006%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20learning%20curve%20of%20nurses%20for%20the%20assessment%20of%20swollen%20and%20tender%20joints%20in%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20P.%22%2C%22lastName%22%3A%22Cheung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Dougados%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Andre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Chal%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Chary-Valckenaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Dernis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghislaine%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melanie%22%2C%22lastName%22%3A%22Gilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gael%22%2C%22lastName%22%3A%22Mouterde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Pavy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Pouyol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Marhadour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Richette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Ruyssen-Witrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Soubrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minh%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gossec%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20In%20rheumatoid%20arthritis%20%28RA%29%2C%20nurses%20are%20now%20increasingly%20involved%20in%20joint%20count%20assessment%20but%20training%20is%20not%20standardized.%20The%20aim%20was%20to%20evaluate%20and%20describe%20the%20learning%20curve%20of%20nurses%20for%20the%20assessment%20of%20swollen%20and%20tender%20joints%20in%20RA.%5CnMETHOD%3A%20Twenty%20nurses%20from%20university%20rheumatology%20centres%20inexperienced%20with%20joint%20counts%20were%20allocated%20to%20a%20rheumatologist%20from%20their%20centre%20%28teacher%29.%20Acquisition%20of%20skills%20consisted%20of%20Phase%201%3A%20%28training%29%2C%20a%20centralized%204hour%20training%20session%2C%20with%20%28a%29%20lecture%20and%20demonstration%2C%20and%20%28b%29%20practical%20sessions%20on%20patients%20with%20their%20teachers%2C%20followed%20by%20Phase%202%3A%20%28practice%29%20involving%20further%20practice%20on%2020%20patients%20in%20their%20own%20hospitals.%20Primary%20outcome%20was%20achievement%20of%20adequate%20swollen%20joint%20agreement%20between%20nurse%20and%20their%20teacher%20%28%26quot%3Bgold%20standard%26quot%3B%29%20at%20the%20%26quot%3Bjoint%26quot%3B%20level%20defined%20by%20prevalence%20adjusted%20biased%20adjusted%20kappa%20%28PABAK%29%26gt%3B0.60.%20Agreement%20at%20the%20%26quot%3Bpatient%26quot%3B%20level%20of%20swollen%20joint%20count%20%28SJC%29%2C%20tender%20joint%20count%20%28TJC%29%20as%20well%20as%20DAS28%20between%20nurse%20and%20their%20teacher%20were%20assessed%20with%20intra-class%20correlation%20coefficients%20%28ICC%29.%5CnRESULTS%3A%20During%20the%20training%20phase%2C%2075%25%20of%20nurses%20achieved%20a%20swollen%20joint%20PABAK%26gt%3B0.60%20when%20compared%20with%20their%20teachers%2C%20which%20further%20improved%20to%2089%25%20after%20the%2020%20practice%20patients%20%28Phase%202%29.%20Median%20swollen%20joint%20PABAK%20improved%20from%200.64%20%28Q1%3AQ3%200.55%2C0.86%29%20to%200.83%20%28Q1%3AQ3%200.77%2C1%29%20by%20the%20end%20of%20Phase%202.%20At%20the%20%26quot%3Bpatient%26quot%3B%20level%2C%20SJC%20agreement%20remained%20globally%20stable%20%28ICC%2C%200.52%20to%200.66%29%2C%20while%20TJC%20and%20DAS28%20agreement%20remained%20excellent%20throughout.%5CnCONCLUSION%3A%20Nurses%20inexperienced%20in%20joint%20counts%20were%20able%20to%20achieve%20excellent%20agreement%20with%20their%20teachers%20in%20assessment%20of%20tender%20and%20swollen%20joints%20through%20a%20short%20training%20session%3B%20practice%20further%20enhanced%20this%20agreement.%20Larger%20longitudinal%20studies%20are%20required%20to%20assess%20skills%20retention.%22%2C%22date%22%3A%22Mar%202014%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2013.06.006%22%2C%22ISSN%22%3A%221778-7254%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A37Z%22%7D%7D%2C%7B%22key%22%3A%2279MKR4XC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zink%20et%20al.%22%2C%22parsedDate%22%3A%222013-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZink%2C%20J.%2C%20Souteyrand%2C%20P.%2C%20Guis%2C%20S.%2C%20Chagnaud%2C%20C.%2C%20Le%20Fur%2C%20Y.%2C%20Militianu%2C%20D.%2C%20Mattei%2C%20J.P.%2C%20Rozenbaum%2C%20M.%2C%20Rosner%2C%20I.%2C%20Boudinet%2C%20H.%2C%20Bernard%2C%20M.%20and%20Bendahan%2C%20D.%20%282013%29%20%26%23x201C%3BSemi-Automatic%20Quantitative%20Investigation%20of%20Wrist%20Cartilage%20in%20Humans%20Using%203t%20Mri%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20the%20Rheumatic%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2C%2072%2C%20pp.%201018%26%23x2013%3B1019.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Semi-Automatic%20Quantitative%20Investigation%20of%20Wrist%20Cartilage%20in%20Humans%20Using%203t%20Mri%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Zink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Souteyrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Le%20Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Militianu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Rozenbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Rosner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Boudinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22JUN%202013%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220003-4967%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SVI8UJ6H%22%2C%225Z6CVJGB%22%2C%22NW6SZQBR%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222014-12-19T08%3A25%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22IURAQW99%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Guis%20et%20al.%22%2C%22parsedDate%22%3A%222013-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuis%2C%20S.%2C%20Mattei%2C%20J.-P.%20and%20Bendahan%2C%20D.%20%282013%29%20%26%23x201C%3BToxic%20myopathies%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%2C%20bone%2C%20spine%3A%20revue%20du%20rhumatisme%26lt%3B%5C%2Fi%26gt%3B%2C%2080%283%29%2C%20pp.%20231%26%23x2013%3B233.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2012.10.008%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2012.10.008%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Toxic%20myopathies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22May%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2012.10.008%22%2C%22ISSN%22%3A%221778-7254%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22XJU3QETE%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cheung%20et%20al.%22%2C%22parsedDate%22%3A%222013-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCheung%2C%20P.P.%2C%20Dougados%2C%20M.%2C%20Andre%2C%20V.%2C%20Balandraud%2C%20N.%2C%20Chales%2C%20G.%2C%20Chary-Valckenaere%2C%20I.%2C%20Chatelus%2C%20E.%2C%20Dernis%2C%20E.%2C%20Gill%2C%20G.%2C%20Gilson%2C%20M.%2C%20Guis%2C%20S.%2C%20Mouterde%2C%20G.%2C%20Pavy%2C%20S.%2C%20Pouyol%2C%20F.%2C%20Marhadour%2C%20T.%2C%20Richette%2C%20P.%2C%20Ruyssen-Witrand%2C%20A.%2C%20Soubrier%2C%20M.%20and%20Gossec%2C%20L.%20%282013%29%20%26%23x201C%3BImproving%20agreement%20in%20assessment%20of%20synovitis%20in%20rheumatoid%20arthritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%2C%20Bone%2C%20Spine%3A%20Revue%20Du%20Rhumatisme%26lt%3B%5C%2Fi%26gt%3B%2C%2080%282%29%2C%20pp.%20155%26%23x2013%3B159.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2012.07.014%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2012.07.014%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Improving%20agreement%20in%20assessment%20of%20synovitis%20in%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20P.%22%2C%22lastName%22%3A%22Cheung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Dougados%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Andre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Chales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Chary-Valckenaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Chatelus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Dernis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghislaine%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Gilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gael%22%2C%22lastName%22%3A%22Mouterde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Pavy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Pouyol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Marhadour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Richette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Ruyssen-Witrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Soubrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gossec%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Synovitis%20assessment%20through%20evaluation%20of%20swollen%20joints%20is%20integral%20in%20steering%20treatment%20decisions%20in%20rheumatoid%20arthritis%20%28RA%29.%20However%2C%20there%20is%20high%20inter-observer%20variation.%20The%20objective%20was%20to%20assess%20if%20a%20short%20collegiate%20consensus%20would%20improve%20swollen%20joint%20agreement%20between%20rheumatologists%20and%20whether%20this%20was%20affected%20by%20experience.%5CnMETHODS%3A%20Eighteen%20rheumatologists%20from%20French%20university%20rheumatology%20units%20participated%20in%20three%2030%20minutes%20rounds%20over%20a%20half%20day%20meeting%20evaluating%20joint%20counts%20of%20RA%20patients%20in%20small%20groups%2C%20followed%20by%20short%20consensus%20discussions.%20Agreement%20was%20evaluated%20at%20the%20end%20of%20each%20round%20as%20follows%3A%20%28i%29%20global%20agreement%20of%20swollen%20joints%20%28ii%29%20swollen%20joint%20agreement%20according%20to%20level%20of%20experience%20of%20the%20rheumatologist%20%28iii%29%20swollen%20joint%20count%20and%20%28iv%29%20agreement%20of%20disease%20activity%20state%20according%20to%20the%20Disease%20Activity%20Score%20%28DAS28%29.%20Agreement%20was%20calculated%20using%20percentage%20agreement%20and%20kappa.%5CnRESULTS%3A%20Global%20agreement%20of%20swollen%20joints%20failed%20to%20improve%20%28kappa%200.50%20to%200.52%29%20at%20the%20joint%20level.%20Agreement%20between%20seniors%20did%20not%20improve%20but%20agreement%20between%20newly%20qualified%20rheumatologists%20and%20their%20senior%20peer%2C%20which%20was%20initially%20poor%20%28kappa%200.28%29%2C%20improved%20significantly%20%28to%200.54%29%20at%20the%20end%20of%20the%20consensus%20exercises.%20Concordance%20of%20DAS28%20activity%20states%20improved%20from%2071%25%20to%2087%25.%5CnCONCLUSION%3A%20Consensus%20exercises%20for%20swollen%20joint%20assessment%20is%20worthwhile%20and%20may%20potentially%20improve%20agreement%20between%20clinicians%20in%20clinical%20synovitis%20and%20disease%20activity%20state%2C%20benefit%20was%20mostly%20observed%20in%20newly%20qualified%20rheumatologists.%22%2C%22date%22%3A%22Mar%202013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2012.07.014%22%2C%22ISSN%22%3A%221778-7254%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22ESP2GJ93%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cammilleri%20et%20al.%22%2C%22parsedDate%22%3A%222013%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCammilleri%2C%20S.%2C%20Guzian%2C%20M.C.%2C%20Mattei%2C%20J.-P.%2C%20Mundler%2C%20O.%20and%20Guis%2C%20S.%20%282013%29%20%26%23x201C%3BWhole-Body%20%2818%29%20FDG-PET%20in%20an%20Arthritis%20Paraneoplastic%20Syndrome%20Revealed%20an%20Underlying%20Hematological%20Neoplasm%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BCase%20Reports%20in%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%202013%2C%20p.%20594704.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1155%5C%2F2013%5C%2F594704%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1155%5C%2F2013%5C%2F594704%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Whole-Body%20%2818%29%20FDG-PET%20in%20an%20Arthritis%20Paraneoplastic%20Syndrome%20Revealed%20an%20Underlying%20Hematological%20Neoplasm%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Cammilleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Caroline%22%2C%22lastName%22%3A%22Guzian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Mundler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22We%20showed%20the%20first%20image%20of%20%2818%29FDG-PET%2C%20which%20leads%20to%20a%20diagnosis%20of%20lymphoma%20in%20an%20atypical%20polyarthritis.%20About%204%25%20of%20patients%20with%20lymphoma%20or%20leukemia%20suffered%20from%20rheumatologic%20paraneoplastic%20symptoms%20like%20arthralgia%20and%20about%2010%25%20of%20the%20patients%20with%20rheumatologic%20or%20neurologic%20clinical%20symptoms%20develop%20a%20solid%20cancer%20or%20hematological%20neoplasm.%20%2818%29FDG-PET%20is%20an%20interesting%20exam%20to%20identify%20an%20underlying%20malignancy%20when%20a%20paraneoplastic%20syndrome%20is%20suspected%3B%20it%20can%20detect%20the%20primitive%20lesion%20and%5C%2For%20the%20metastasis%20lesions.%20The%20use%20of%20the%20%2818%29FDG-PET%20can%20help%20to%20detect%20earlier%20hematological%20neoplasm%20in%20cases%20of%20paraneoplastic%20syndrome%20without%20a%20determined%20cause%20and%20to%20treat%20more%20rapidly%20and%20specifically%20the%20patient.%22%2C%22date%22%3A%222013%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1155%5C%2F2013%5C%2F594704%22%2C%22ISSN%22%3A%221687-9627%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22WWN92H6F%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22D%27Agostino%20et%20al.%22%2C%22parsedDate%22%3A%222012-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BD%26%23x2019%3BAgostino%2C%20M.-A.%2C%20Saraux%2C%20A.%2C%20Chary-Valckenaere%2C%20I.%2C%20Marcelli%2C%20C.%2C%20Guis%2C%20S.%2C%20Gaudin%2C%20P.%2C%20Aegerter%2C%20P.%2C%20Jousse-Joulin%2C%20S.%2C%20Loeuille%2C%20D.%2C%20Judet%2C%20O.%2C%20Lecoq%2C%20B.%2C%20Hacquard-Bouder%2C%20C.%2C%20Grange%2C%20L.%2C%20Guzian%2C%20M.C.%2C%20Blum%2C%20A.%2C%20Chagnaud%2C%20C.%2C%20Leboime%2C%20A.%2C%20Monnet%2C%20D.%2C%20Rat%2C%20A.-C.%2C%20Timsit%2C%20M.A.%2C%20Said-Nahal%2C%20R.%20and%20Breban%2C%20M.%20%282012%29%20%26%23x201C%3BCan%20we%20improve%20the%20diagnosis%20of%20spondyloarthritis%20in%20patients%20with%20uncertain%20diagnosis%3F%20The%20EchoSpA%20prospective%20multicenter%20French%20cohort%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%2C%20Bone%2C%20Spine%3A%20Revue%20Du%20Rhumatisme%26lt%3B%5C%2Fi%26gt%3B%2C%2079%286%29%2C%20pp.%20586%26%23x2013%3B590.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2012.02.007%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2012.02.007%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Can%20we%20improve%20the%20diagnosis%20of%20spondyloarthritis%20in%20patients%20with%20uncertain%20diagnosis%3F%20The%20EchoSpA%20prospective%20multicenter%20French%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria-Antonietta%22%2C%22lastName%22%3A%22D%27Agostino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Saraux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Chary-Valckenaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Marcelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Aegerter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Jousse-Joulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Loeuille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Judet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Lecoq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Hacquard-Bouder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Grange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Caroline%22%2C%22lastName%22%3A%22Guzian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Blum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariane%22%2C%22lastName%22%3A%22Leboime%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Monnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Christine%22%2C%22lastName%22%3A%22Rat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Timsit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roula%22%2C%22lastName%22%3A%22Said-Nahal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Breban%22%7D%5D%2C%22abstractNote%22%3A%22Power%20Doppler%20ultrasound%20%28PDUS%29%20has%20proved%20to%20be%20a%20highly%20sensitive%20tool%20for%20assessing%20enthesitis%20in%20spondyloarthritis%20%28SpA%29.%20In%20patients%20with%20a%20suspected%20SpA%2C%20diagnosis%20could%20be%20improved%20by%20detecting%20enthesitis%20with%20PDUS.%5CnOBJECTIVE%3A%20To%20evaluate%20the%20performance%20of%20PDUS%20for%20the%20diagnosis%20of%20SpA%20alone%20or%20combined%20with%20other%20clinical%2C%20laboratory%20and%20imaging%20findings%20in%20patients%20consulting%20for%20a%20suspected%20SpA.%5CnMETHODS%3A%20Prospective%2C%20multicenter%20French%20cohort%20study%20%28Boulogne-Billancourt%2C%20Brest%2C%20Caen%2C%20Grenoble%2C%20Marseille%20and%20Nancy%29.%20Outpatients%20consulting%20for%20symptoms%20suggestive%20of%20SpA%20%28inflammatory%20back%20pain%20%5BIBP%5D%2C%20arthritis%20or%20inflammatory%20arthralgia%20%5BIA%5D%2C%20enthesitis%20or%20dactylitis%20%5BED%5D%2C%20HLA-B27%20positive%20uveitis%20%5BB27%2BU%5D%2C%20familiarity%20for%20SpA%20%5BFam%5D%29%20were%20recruited%20and%20followed%20up%20for%20at%20least%202%20years.%20Sample%20size%20was%20set%20to%20500%20patients%20%28for%20estimated%20prevalence%20of%20SpA%20of%2030%5Cu00b15%25%20after%202%20years%29.%20At%20baseline%2C%20patients%20were%20submitted%20to%20standardized%20physical%20examination%2C%20pelvic%20X-ray%2C%20sacroiliac%20joints%20magnetic%20resonance%20imaging%20%28MRI%29%2C%20HLA-B%20typing%2C%20and%20other%20tests%20judged%20useful%20for%20diagnosis.%20For%20each%20patient%2C%20a%20blinded%20PDUS%20examination%20of%2014%20enthesitic%20sites%20was%20performed%20at%20baseline%20and%20at%20years%201%20and%202.%20Patients%20were%20planned%20to%20be%20followed%20during%205%20years.%20The%20diagnosis%20of%20SpA%20ascertained%20by%20an%20experts%26%23039%3B%20committee%2C%20blind%20to%20PDUS%20results%2C%20after%20at%20least%202%20years%20of%20follow-up%2C%20with%20a%20revaluation%20of%20doubtful%20patients%20at%205%20years%20will%20be%20used%20as%20gold%20standard%20for%20evaluating%20the%20diagnostic%20performance%20of%20PDUS%20and%20the%20best%20diagnostic%20procedure%20by%20combining%20PDUS%2C%20clinical%20symptoms%20and%20other%20tests.%5CnRESULTS%3A%20Between%20January%202005%20and%20September%202007%2C%20489%20patients%20were%20included%20%2896%25%20of%20the%20target%20population%29.%20Nineteen%20patients%20%280.2%25%29%20retired%20their%20informed%20consensus%20or%20were%20lost%20to%20follow-up%20immediately%20after%20their%20inclusion.%20At%20baseline%2C%20mean%20age%20of%20the%20470%20remaining%20patients%20was%2040%20years%2C%20mean%20duration%20of%20symptoms%20was%206.1%20years%3B%2042%25%20of%20them%20were%20HLA-B27%2B%20and%2063%25%20were%20female.%20Primary%20inclusion%20criterion%20was%20IBP%20in%2053%25%2C%20IA%20in%2027%25%2C%20ED%20in%209%25%2C%20B27%2BU%20in%208%25%20and%20Fam%20in%204%25.%20Follow-up%20is%20still%20ongoing.%5CnCONCLUSION%3A%20We%20have%20set%20up%20a%20unique%20diagnostic%20cohort%20which%20includes%20the%20entire%20spectrum%20of%20SpA%20manifestations.%20By%20using%20PDUS%20we%20expected%20to%20improve%20the%20diagnostic%20procedure%20of%20SpA.%22%2C%22date%22%3A%22Dec%202012%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2012.02.007%22%2C%22ISSN%22%3A%221778-7254%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A40%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22UISDE4T3%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Devauchelle-Pensec%20et%20al.%22%2C%22parsedDate%22%3A%222012-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDevauchelle-Pensec%2C%20V.%2C%20D%26%23x2019%3BAgostino%2C%20M.A.%2C%20Marion%2C%20J.%2C%20Lapierre%2C%20M.%2C%20Jousse-Joulin%2C%20S.%2C%20Colin%2C%20D.%2C%20Chary-Valckenaere%2C%20I.%2C%20Marcelli%2C%20C.%2C%20Loeuille%2C%20D.%2C%20Aegerter%2C%20P.%2C%20Guis%2C%20S.%2C%20Gaudin%2C%20P.%2C%20Breban%2C%20M.%2C%20Saraux%2C%20A.%20and%20Study%20Group%20of%20Spondylarthritis%20%282012%29%20%26%23x201C%3BComputed%20tomography%20scanning%20facilitates%20the%20diagnosis%20of%20sacroiliitis%20in%20patients%20with%20suspected%20spondylarthritis%3A%20results%20of%20a%20prospective%20multicenter%20French%20cohort%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BArthritis%20and%20Rheumatism%26lt%3B%5C%2Fi%26gt%3B%2C%2064%285%29%2C%20pp.%201412%26%23x2013%3B1419.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.33466%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.33466%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Computed%20tomography%20scanning%20facilitates%20the%20diagnosis%20of%20sacroiliitis%20in%20patients%20with%20suspected%20spondylarthritis%3A%20results%20of%20a%20prospective%20multicenter%20French%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Devauchelle-Pensec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Antonietta%22%2C%22lastName%22%3A%22D%27Agostino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Marion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lapierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Jousse-Joulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danielle%22%2C%22lastName%22%3A%22Colin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Chary-Valckenaere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Marcelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Loeuille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Aegerter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Breban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Saraux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Study%20Group%20of%20Spondylarthritis%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20assess%20the%20performance%20of%20computed%20tomography%20%28CT%29%20scanning%20for%20ascertaining%20sacroiliitis%20in%20patients%20with%20suspected%20spondylarthritis%20%28SpA%29.%5CnMETHODS%3A%20The%20Echography%20in%20Spondylarthritis%20French%20cohort%20consists%20of%20489%20patients%20with%20suspected%20SpA.%20At%20baseline%2C%20all%20patients%20underwent%20clinical%20examination%2C%20HLA-B%20typing%2C%20and%20pelvic%20radiography.%20Pelvic%20CT%20scanning%20was%20performed%20if%20sacroiliitis%20on%20radiography%20was%20considered%20uncertain%20or%20if%20patients%20presented%20with%20buttock%20pain%20duration%20of%20%26gt%3B6%20months.%20A%20set%20of%20100%20paired%20radiographs%20and%20CT%20scans%20was%20read%20in%20a%20blinded%20manner%20by%202%20radiologists%2C%20and%20the%20kappa%20coefficient%20was%20used%20to%20assess%20their%20interreader%20reliability.%20One%20of%20the%20radiologists%20read%20the%20173%20available%20pairs%20of%20radiographs%20and%20CT%20scans%20performed%20at%20baseline.%5CnRESULTS%3A%20After%20training%2C%20interreader%20reliability%20was%20moderate%20for%20sacroiliitis%20grading%20on%20radiographs%20%28%5Cu03ba%20%3D%200.59%29%2C%20excellent%20on%20CT%20scans%20%28%5Cu03ba%20%3D%200.91%29%2C%20and%20excellent%20for%20ascertaining%20sacroiliitis%20on%20both%20radiographs%20%28%5Cu03ba%20%3D%201%29%20and%20CT%20scans%20%28%5Cu03ba%20%3D%200.96%29.%20The%20first%20and%20second%20readers%20considered%20the%20quality%20of%20imaging%20to%20be%20excellent%20in%2066%25%20and%2067%25%2C%20respectively%2C%20of%20the%20radiographs%20%28%5Cu03ba%20%3D%200.88%29%20and%20in%2093%25%20and%2092%25%2C%20respectively%2C%20of%20the%20CT%20scans%20%28%5Cu03ba%20%3D%200.93%29.%20Concordance%20between%20radiographs%20and%20CT%20scans%20was%20low%20for%20sacroiliitis%20grading%20%28%5Cu03ba%20%3D%200.08%29%20or%20ascertainment%20%28%5Cu03ba%20%3D%200.16%29.%20Definite%20sacroiliitis%20was%20ascertained%20on%20radiographs%20in%206%20patients%20%283.5%25%29%20%28confirmed%20by%20CT%20scans%20in%204%20patients%29%20and%20on%20CT%20scans%20in%2032%20patients%20%2818.5%25%29.%20A%20history%20of%20uveitis%20was%20associated%20with%20definite%20sacroiliitis%20on%20radiographs%20%28P%20%3D%200.04%29%20and%20CT%20scans%20%28P%20%26lt%3B%200.0001%29.%5CnCONCLUSION%3A%20Definite%20sacroiliitis%20was%20underestimated%20by%20radiography%2C%20as%20compared%20to%20CT%20scanning.%20CT%20scanning%20should%20facilitate%20the%20diagnosis%20of%20ankylosing%20spondylitis%20in%20patients%20with%20suspected%20SpA.%22%2C%22date%22%3A%22May%202012%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fart.33466%22%2C%22ISSN%22%3A%221529-0131%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-11-21T08%3A40%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22VF7FGHZC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222011-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBonnet%2C%20N.%2C%20Guis%2C%20S.%2C%20Drancourt%2C%20M.%2C%20Brouqui%2C%20P.%20and%20Berbis%2C%20P.%20%282011%29%20%26%23x201C%3BBorreliosis%20in%20a%20patient%20treated%20with%20anti-TNF%26%23x3B1%3B%20therapy%3A%20first%20case%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology%3A%20JEADV%26lt%3B%5C%2Fi%26gt%3B%2C%2025%283%29%2C%20pp.%20367%26%23x2013%3B368.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fj.1468-3083.2010.03724.x%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fj.1468-3083.2010.03724.x%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Borreliosis%20in%20a%20patient%20treated%20with%20anti-TNF%5Cu03b1%20therapy%3A%20first%20case%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Drancourt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Brouqui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Berbis%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Mar%202011%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fj.1468-3083.2010.03724.x%22%2C%22ISSN%22%3A%221468-3083%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22S78B4FRG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Faucher%20et%20al.%22%2C%22parsedDate%22%3A%222010-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFaucher%2C%20B.%2C%20Stein%2C%20P.%2C%20Granel%2C%20B.%2C%20Weiller%2C%20P.-J.%2C%20Disdier%2C%20P.%2C%20Serratrice%2C%20J.%2C%20Harl%26%23xE9%3B%2C%20J.R.%2C%20Durand%2C%20J.M.%2C%20Frances%2C%20Y.%2C%20Guis%2C%20S.%2C%20Pham%2C%20T.%2C%20Bardin%2C%20N.%20and%20Sanmarco%2C%20M.%20%282010%29%20%26%23x201C%3BLow%20prevalence%20of%20anti-RNA%20polymerase%20III%20antibodies%20in%20a%20French%20scleroderma%20population%3A%20anti-RNA%20polymerase%20III%20scleroderma%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Internal%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2C%2021%282%29%2C%20pp.%20114%26%23x2013%3B117.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejim.2010.01.004%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejim.2010.01.004%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Low%20prevalence%20of%20anti-RNA%20polymerase%20III%20antibodies%20in%20a%20French%20scleroderma%20population%3A%20anti-RNA%20polymerase%20III%20scleroderma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Faucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Stein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Granel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Jean%22%2C%22lastName%22%3A%22Weiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Disdier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Serratrice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Robert%22%2C%22lastName%22%3A%22Harl%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Marc%22%2C%22lastName%22%3A%22Durand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Frances%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thao%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Bardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marielle%22%2C%22lastName%22%3A%22Sanmarco%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Anti-RNA%20polymerase%20III%20antibodies%20%28anti-RNAP%20III%29%20have%20been%20reported%20as%20potential%20immune%20markers%20of%20Systemic%20Sclerosis%20%28SSc%29.%20Until%20now%2C%20their%20clinical%20use%20was%20disregarded%20because%20of%20technical%20difficulties%20to%20perform%20immunoprecipitation.%20Recently%2C%20ELISA%20kits%20became%20commercially%20available%20allowing%20an%20easy%20detection%20of%20anti-RNAP%20III.%20We%20intended%20to%20clarify%20the%20relevance%20of%20these%20antibodies%20in%20the%20diagnosis%20of%20SSc%20by%20ELISA%20detection.%5CnMETHODS%3A%20The%20prevalence%20of%20anti-RNAP%20III%20was%20analyzed%20using%20two%20ELISA%20kits%20in%2050%20consecutive%20SSc%20patients%20from%20Marseilles%20in%20South%20of%20France.%20Controls%20included%2066%20patients%20with%20other%20systemic%20autoimmune%20diseases%2C%2034%20viral%20diseases%20and%2050%20healthy%20subjects.%20Positive%20results%20with%20at%20least%20one%20ELISA%20kit%20were%20controlled%20by%20immunoprecipitation%20which%20is%20the%20reference%20assay.%5CnRESULTS%3A%20In%20this%20study%2C%20positivity%20for%20anti-centromere%20and%5C%2For%20anti-topoisomerase%20I%20antibodies%20was%20observed%20in%2084%25%20of%20SSc%20patients.%20The%20prevalence%20of%20anti-RNAP%20III%20in%20SSc%20patients%20was%200%25%20to%206%25%20%283%5C%2F50%29%20depending%20on%20the%20ELISA%20kit%20and%20only%202%25%20by%20immunoprecipitation.%20Concerning%20controls%2C%20two%20rheumatoid%20arthritis%20patients%20were%20positive%20using%20ELISA%20%286%25%29%2C%20including%20one%20with%20immunoprecipitation%20confirmation.%20No%20anti-RNAP%20III%20was%20detected%20in%20systemic%20lupus%20erythematosus%20patients.%20Three%20blood%20donors%20and%20one%20viral%20disease%20control%20were%20positive%20using%20ELISA%2C%20but%20all%20were%20negative%20by%20immunoprecipitation.%5CnCONCLUSIONS%3A%20Anti-RNAP%20III%20was%20rarely%20detected%20in%20a%20French%20population%20of%20SSc%20patients.%20Their%20prevalence%20was%20even%20lower%20than%20the%20one%20observed%20in%20rheumatoid%20arthritis%20controls.%20Therefore%20local%20immunologic%20profiles%20should%20be%20established%20before%20deciding%20a%20change%20in%20clinical%20practice%20for%20SSc%20immune%20screening.%22%2C%22date%22%3A%22Apr%202010%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejim.2010.01.004%22%2C%22ISSN%22%3A%221879-0828%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22ZDBWI58K%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222010-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBonnet%2C%20N.%2C%20Guis%2C%20S.%2C%20Koeppel%2C%20M.-C.%2C%20Roudier%2C%20J.%2C%20Grimaud%2C%20J.-C.%2C%20Jean-Pastor%2C%20M.-J.%20and%20Berbis%2C%20P.%20%282010%29%20%26%23x201C%3B%5BCutaneous%20events%20during%20anti-TNF%20alpha%20therapy%3A%20a%20prospective%20observational%20study%20of%2041%20cases%5D%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnales%20De%20Dermatologie%20Et%20De%20V%26%23xE9%3Bn%26%23xE9%3Br%26%23xE9%3Bologie%26lt%3B%5C%2Fi%26gt%3B%2C%20137%281%29%2C%20pp.%2012%26%23x2013%3B20.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annder.2009.12.003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annder.2009.12.003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BCutaneous%20events%20during%20anti-TNF%20alpha%20therapy%3A%20a%20prospective%20observational%20study%20of%2041%20cases%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.-C.%22%2C%22lastName%22%3A%22Koeppel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-C.%22%2C%22lastName%22%3A%22Grimaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.-J.%22%2C%22lastName%22%3A%22Jean-Pastor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Berbis%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20cutaneous%20adverse%20effects%20of%20TNFalpha%20inhibitors%20and%20their%20potential%20implication%20in%20the%20onset%20of%20associated%20dermatoses%20remain%20poorly%20understood.%5CnPURPOSE%3A%20To%20describe%20the%20different%20clinical%20dermatological%20situations%20seen%20in%20patients%20treated%20with%20TNFalpha%20inhibitors.%5CnPATIENTS%20AND%20METHODS%3A%20We%20conducted%20a%20prospective%2C%20observational%20study%20of%20patients%20followed%20at%20the%20Dermatology%20Department%20of%20the%20CHU%20Nord%20university%20teaching%20hospital%20of%20Marseilles.%20All%20patients%2C%20referred%20by%20various%20departments%2C%20were%20treated%20with%20TNFalpha%20inhibitors%20and%20presented%20cutaneous%20events.%5CnRESULTS%3A%20Forty-one%20patients%20were%20included%20in%20the%20study.%20Various%20cutaneous%20manifestations%20were%20observed%2C%20including%3A%2015%20psoriatic%20rashes%2C%20six%20skin%20infections%2C%20three%20eczema%20rashes%2C%20three%20cases%20of%20lupic%20syndrome%2C%20two%20anaphylactic%20reactions%20to%20infusion%20and%20two%20cutaneous%20drug%20reactions.%20An%20original%20case%20of%20parapsoriasis%20was%20observed.%20Cutaneous%20tumors%20are%20rarely%20described.%5CnDISCUSSION%3A%20This%20study%20confirms%20the%20multiple%20clinical%20dermatological%20situations%20observed%20in%20patients%20treated%20with%20TNFalpha%20inhibitors%20and%20illustrates%20the%20need%20for%20good%20coordination%20between%20dermatologists%20and%20other%20specialists%20in%20order%20to%20ensure%20optimal%20management%20of%20this%20population.%22%2C%22date%22%3A%22Jan%202010%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annder.2009.12.003%22%2C%22ISSN%22%3A%220151-9638%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22C3M6ICAE%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rak%20et%20al.%22%2C%22parsedDate%22%3A%222009-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRak%2C%20J.M.%2C%20Maestroni%2C%20L.%2C%20Balandraud%2C%20N.%2C%20Guis%2C%20S.%2C%20Boudinet%2C%20H.%2C%20Guzian%2C%20M.C.%2C%20Yan%2C%20Z.%2C%20Azzouz%2C%20D.%2C%20Auger%2C%20I.%2C%20Roudier%2C%20C.%2C%20Martin%2C%20M.%2C%20Didelot%2C%20R.%2C%20Roudier%2C%20J.%20and%20Lambert%2C%20N.C.%20%282009%29%20%26%23x201C%3BTransfer%20of%20the%20shared%20epitope%20through%20microchimerism%20in%20women%20with%20rheumatoid%20arthritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BArthritis%20and%20Rheumatism%26lt%3B%5C%2Fi%26gt%3B%2C%2060%281%29%2C%20pp.%2073%26%23x2013%3B80.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.24224%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.24224%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transfer%20of%20the%20shared%20epitope%20through%20microchimerism%20in%20women%20with%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Rak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Maestroni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Boudinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Guzian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z.%22%2C%22lastName%22%3A%22Yan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Azzouz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Didelot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20C.%22%2C%22lastName%22%3A%22Lambert%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Rheumatoid%20arthritis%20%28RA%29%20is%20an%20autoimmune%20disease%20that%20affects%20mostly%20women%20and%20is%20associated%20with%20HLA-DRB1%20genes%20having%20in%20common%20a%20shared%20epitope%20sequence.%20In%20parallel%2C%20cells%20and%5C%2For%20DNA%20originating%20from%20pregnancy%20%28microchimerism%29%20persist%20for%20decades%20and%20could%20contribute%20to%20autoimmunity.%20The%20aim%20of%20this%20study%20was%20to%20examine%20whether%20microchimerism%20may%20be%20a%20source%20of%20the%20shared%20epitope%20among%20women%20with%20RA.%5CnMETHODS%3A%20Women%20with%20RA%20and%20healthy%20women%20who%20lacked%20RA-associated%20genes%20such%20as%20HLA-DRB1%2A01%20%28n%3D33%20and%20n%3D46%2C%20respectively%29%20and%5C%2For%20HLA-DRB1%2A04%20%28n%3D48%20and%20n%3D64%2C%20respectively%29%2C%20were%20tested%20for%20DRB1%2A01%20or%20DRB1%2A04%20microchimerism%20by%20HLA-specific%20quantitative%20polymerase%20chain%20reaction%20assays.%20As%20controls%2C%20alleles%20not%20associated%20with%20RA%20%28DQB1%2A02%20and%20DRB1%2A15%5C%2F16%29%20were%20also%20analyzed.%5CnRESULTS%3A%20Compared%20with%20healthy%20women%2C%20women%20%2842%25%20with%20RA%20had%20a%20higher%20frequency%20and%20higher%20levels%20of%20DRB1%2A04%20microchimerism%20versus%208%25%3B%20P%3D0.00002%29%20as%20well%20as%20DRB1%2A01%20microchimerism%20%2830%25%20versus%204%25%3B%20P%3D0.0015%29.%20Moreover%2C%20no%20difference%20in%20microchimerism%20was%20observed%20for%20alleles%20not%20associated%20with%20RA.%5CnCONCLUSION%3A%20Women%20with%20RA%20had%20microchimerism%20with%20RA-associated%20HLA%20alleles%2C%20but%20not%20with%20non-RA-associated%20HLA%20alleles%2C%20more%20often%20and%20at%20higher%20levels%20compared%20with%20healthy%20women.%20These%20observations%20are%20the%20first%20to%20indicate%20that%20microchimerism%20can%20contribute%20to%20the%20risk%20of%20an%20autoimmune%20disease%20by%20providing%20HLA%20susceptibility%20alleles.%22%2C%22date%22%3A%22Jan%202009%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fart.24224%22%2C%22ISSN%22%3A%220004-3591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A39Z%22%7D%7D%2C%7B%22key%22%3A%2232VC5VPM%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Charpin%20et%20al.%22%2C%22parsedDate%22%3A%222009%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCharpin%2C%20C.%2C%20Guis%2C%20S.%2C%20Colson%2C%20P.%2C%20Borentain%2C%20P.%2C%20Matt%26%23xE9%3Bi%2C%20J.-P.%2C%20Alcaraz%2C%20P.%2C%20Balandraud%2C%20N.%2C%20Thomachot%2C%20B.%2C%20Roudier%2C%20J.%20and%20G%26%23xE9%3Brolami%2C%20R.%20%282009%29%20%26%23x201C%3BSafety%20of%20TNF-blocking%20agents%20in%20rheumatic%20patients%20with%20serology%20suggesting%20past%20hepatitis%20B%20state%3A%20results%20from%20a%20cohort%20of%2021%20patients%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BArthritis%20Research%20%26amp%3B%20Therapy%26lt%3B%5C%2Fi%26gt%3B%2C%2011%286%29%2C%20p.%20R179.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Far2868%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Far2868%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Safety%20of%20TNF-blocking%20agents%20in%20rheumatic%20patients%20with%20serology%20suggesting%20past%20hepatitis%20B%20state%3A%20results%20from%20a%20cohort%20of%2021%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Charpin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Colson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Borentain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Matt%5Cu00e9i%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Alcaraz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Thomachot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ren%5Cu00e9%22%2C%22lastName%22%3A%22G%5Cu00e9rolami%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Reactivation%20of%20hepatitis%20B%20virus%20%28HBV%29%20infection%20in%20patients%20with%20past%20infection%20has%20been%20described%20in%205%25%20to%2010%25%20of%20individuals%20undergoing%20immunosuppressive%20therapies.%20No%20data%20are%20available%20to%20date%20on%20the%20outcome%20of%20patients%20treated%20by%20tumour%20necrosis%20factor-alpha%20%28TNFalpha%29%20inhibitors%20for%20chronic%20arthritis%20with%20a%20serological%20pattern%20of%20past%20HBV%20infection.%20The%20aim%20of%20our%20study%20was%20to%20monitor%20HBV%20markers%20in%20HBV%20surface%20antigen%20%28HBsAg%29-negative%5C%2Fanti-HBcAb-positive%20patients%20treated%20with%20a%20TNFalpha%20inhibitor%20for%20inflammatory%20arthritides.%5CnMETHODS%3A%20Twenty-one%20HBsAg-negative%5C%2Fanti-HBcAb-positive%20patients%20were%20included.%20HBV%20serological%20patterns%20were%20compared%20with%20those%20determined%20before%20starting%20TNFalpha%20inhibitors.%20Serum%20HBV%20DNA%20testing%20by%20polymerase%20chain%20reaction%20was%20additionally%20performed.%20Spearman%20correlation%20analysis%20was%20used%20and%20P%20%26lt%3B%200.05%20was%20chosen%20as%20the%20significance%20threshold.%5CnRESULTS%3A%20Before%20starting%20therapy%2C%20mean%20anti-HBsAb%20titre%20was%20725%20IU%5C%2FL%2C%20no%20patient%20had%20an%20anti-HBsAb%20titre%20%26lt%3B10%20IU%5C%2FL%2C%20and%2018%20patients%20had%20an%20anti-HBsAb%20%26gt%3B100%20IU%5C%2FL.%20At%20a%20mean%20time%20of%2027.2%20months%20following%20therapy%20introduction%2C%20mean%20anti-HBsAb%20titre%20was%20675%20IU%5C%2FL%20and%20anti-HBsAb%20titre%20remained%20%26gt%3B100%20IU%5C%2FL%20in%2017%20patients.%20There%20was%20a%20strong%20correlation%20between%20the%20first%20and%20second%20anti-HBsAb%20titres%20%28r%20%3D%200.98%2C%20P%20%3D%200.013%29.%20Moreover%2C%20no%20patient%20had%20an%20anti-HBsAb%20titre%20below%2010%20IU%5C%2FL%20or%20HBV%20reactivation%20%28HBsAg%20seroreversion%20or%20positive%20HBV%20DNA%20detection%29.%20However%2C%20the%20anti-HBsAb%20titre%20decreased%20by%20more%20than%2030%25%20in%206%20patients.%20The%20mean%20anti-HBsAb%20titre%20at%20baseline%20was%20significantly%20lower%20%28P%20%3D%200.006%29%20and%20the%20mean%20duration%20of%20anti-TNFalpha%20therapy%2C%20although%20non-significant%20%28P%20%3D%200.09%29%2C%20was%20longer%20in%20these%20six%20patients%20as%20compared%20to%20patients%20without%20a%20decrease%20in%20anti-HBsAb%20titre.%5CnCONCLUSIONS%3A%20Anti-TNFalpha%20treatments%20are%20likely%20to%20be%20safe%20in%20patients%20with%20past%20hepatitis%20B%20serological%20pattern.%20However%2C%20the%20significant%20decrease%20of%20anti-HBsAb%20titre%20observed%20in%20a%20proportion%20of%20patients%20deserves%20HBV%20virological%20follow-up%20in%20these%20patients%2C%20especially%20in%20those%20with%20a%20low%20anti-HBsAb%20titre%20at%20baseline.%22%2C%22date%22%3A%222009%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Far2868%22%2C%22ISSN%22%3A%221478-6362%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%225FGGIEIK%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guis%20et%20al.%22%2C%22parsedDate%22%3A%222008-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuis%2C%20S.%2C%20Schiano%20de%20Colella%2C%20J.-M.%2C%20Bonnet%2C%20N.%2C%20Andrac-Meyer%2C%20L.%2C%20Balandraud%2C%20N.%2C%20Mattei%2C%20J.-P.%2C%20Franck%2C%20B.%2C%20Roudier%2C%20C.%2C%20Roudier%2C%20J.%20and%20Berbis%2C%20P.%20%282008%29%20%26%23x201C%3BCutaneous%20pseudolymphoma%20associated%20with%20a%20TNF-alpha%20inhibitor%20treatment%3A%20etanercept%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20journal%20of%20dermatology%3A%20EJD%26lt%3B%5C%2Fi%26gt%3B%2C%2018%284%29%2C%20pp.%20474%26%23x2013%3B476.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1684%5C%2Fejd.2008.0457%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1684%5C%2Fejd.2008.0457%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cutaneous%20pseudolymphoma%20associated%20with%20a%20TNF-alpha%20inhibitor%20treatment%3A%20etanercept%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Schiano%20de%20Colella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucille%22%2C%22lastName%22%3A%22Andrac-Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Franck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phillippe%22%2C%22lastName%22%3A%22Berbis%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222008%20Jul-Aug%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1684%5C%2Fejd.2008.0457%22%2C%22ISSN%22%3A%221167-1122%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%225Z6CVJGB%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22ZSXUBSW2%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Charpin%20et%20al.%22%2C%22parsedDate%22%3A%222008-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCharpin%2C%20C.%2C%20Balandraud%2C%20N.%2C%20Guis%2C%20S.%2C%20Roudier%2C%20C.%2C%20Toussirot%2C%20E.%2C%20Rak%2C%20J.%2C%20Lambert%2C%20N.%2C%20Martin%2C%20M.%2C%20Reviron%2C%20D.%2C%20Roudier%2C%20J.%20and%20Auger%2C%20I.%20%282008%29%20%26%23x201C%3BHLA-DRB1%2A0404%20is%20strongly%20associated%20with%20high%20titers%20of%20anti-cyclic%20citrullinated%20peptide%20antibodies%20in%20rheumatoid%20arthritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20and%20Experimental%20Rheumatology%26lt%3B%5C%2Fi%26gt%3B%2C%2026%284%29%2C%20pp.%20627%26%23x2013%3B631.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HLA-DRB1%2A0404%20is%20strongly%20associated%20with%20high%20titers%20of%20anti-cyclic%20citrullinated%20peptide%20antibodies%20in%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Charpin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Toussirot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Rak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Reviron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Auger%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20test%20whether%20the%20presence%20of%20RA%20associated%20HLA-DRB1%2A0101%2C%20HLA-DRB1%2A0401%20and%20HLA-DRB1%2A0404%20alleles%20individually%20influences%20anti-cyclic%20citrullinated%20peptide%20antibodies%20%28anti-CCP%29%20production.%5CnMETHODS%3A%20The%20frequency%20of%20anti-CCP%20antibodies%20was%20calculated%20in%20the%20sera%20of%20260%20RA%20patients%20expressing%20either%20two%20%28double%20dose%20genotypes%20SE%2B%5C%2FSE%2B%29%2C%20one%20%28single%20dose%20genotypes%20SE%2B%5C%2FSE-%29%20or%20no%20RA%20associated%20HLA-DR%20alleles%20%28SE-%5C%2FSE-%29.%20Anti-CCP%20antibodies%20titers%20were%20also%20determined.%5CnRESULTS%3A%20RA%20associated%20HLA-DR%20alleles%20are%20not%20mandatory%20for%20production%20of%20anti-CCP.%20We%20found%20that%2068%25%20of%20SE-%5C%2FSE-%20patients%20were%20anti-CCP%20positive.%20There%20was%20no%20significant%20difference%20in%20anti-CCP%20between%20SE%20negative%20patient%20%28SE-%5C%2FSE-%29%20and%20patients%20expressing%20at%20least%20one%20SE%20%28SE%2B%5C%2FSE%2B%20and%20SE%2B%5C%2FSE-%29%20%28p%3D0.140%29.%20We%20observed%20no%20statistical%20difference%20in%20anti-CCP%20between%20RA%20patients%20expressing%20one%20or%20two%20SE%20%2882%25%20vs.%2077%25%2C%20p%3D0.577%29.%20Among%20SE%2B%5C%2FSE-patients%2C%20HLA-DRB1%2A0404%20was%20associated%20with%20anti-CCP%20with%20a%20statistically%20significant%20difference%20compared%20with%20SE%20negative%20patients%20%2890%25%20anti-CCP%20positive%2C%20p%3D0.02%29.%20HLA-DRB1%2A0404%20was%20also%20associated%20with%20high%20titers%20of%20anti%20CCP%20with%20a%20statistically%20significant%20difference%20compared%20with%20HLA-DRB1%2A0401%20and%20HLA-DRB1%2A0101%20patients%20%28p%3D0.025%29.%5CnCONCLUSIONS%3A%20The%20RA-associated%20HLA-DRB1%2A0404%20allele%20was%20the%20most%20strongly%20associated%20with%20the%20presence%20of%20anti-CCP%20in%20RA%20sera.%20Moreover%2C%20HLA-DRB1%2A0404%20patients%20had%20higher%20titers%20of%20anti%20CCP%20than%20patients%20with%20other%20RA%20associated%20HLA-DR%20alleles.%22%2C%22date%22%3A%222008%20Jul-Aug%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220392-856X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%223NXSWBP9%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guis%20et%20al.%22%2C%22parsedDate%22%3A%222007-12-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuis%2C%20S.%2C%20Balandraud%2C%20N.%2C%20Bouvenot%2C%20J.%2C%20Auger%2C%20I.%2C%20Toussirot%2C%20E.%2C%20Wendling%2C%20D.%2C%20Mattei%2C%20J.-P.%2C%20Nogueira%2C%20L.%2C%20Mugnier%2C%20B.%2C%20Legeron%2C%20P.%2C%20Landt%2C%20O.%2C%20Serre%2C%20G.%2C%20Roudier%2C%20J.%20and%20Roudier%2C%20C.%20%282007%29%20%26%23x201C%3BInfluence%20of%20-308%20A%5C%2FG%20polymorphism%20in%20the%20tumor%20necrosis%20factor%20alpha%20gene%20on%20etanercept%20treatment%20in%20rheumatoid%20arthritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BArthritis%20and%20Rheumatism%26lt%3B%5C%2Fi%26gt%3B%2C%2057%288%29%2C%20pp.%201426%26%23x2013%3B1430.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.23092%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.23092%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Influence%20of%20-308%20A%5C%2FG%20polymorphism%20in%20the%20tumor%20necrosis%20factor%20alpha%20gene%20on%20etanercept%20treatment%20in%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Bouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Toussirot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Wendling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonor%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benedicte%22%2C%22lastName%22%3A%22Mugnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Legeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olfert%22%2C%22lastName%22%3A%22Landt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Serre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Roudier%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20determine%20whether%20the%20-308%20A%5C%2FG%20tumor%20necrosis%20factor%20alpha%20%28TNFalpha%29%20gene%20polymorphism%20can%20predict%20the%20outcome%20of%20etanercept%20therapy%20in%2086%20patients%20with%20rheumatoid%20arthritis%20%28RA%29%2C%20as%20already%20observed%20in%20patients%20treated%20with%20infliximab.%5CnMETHODS%3A%20Eighty-six%20RA%20patients%20treated%20with%20etanercept%20were%20genotyped%20for%20-308%20A%5C%2FG%20TNFalpha%20gene%20polymorphism%20by%20polymerase%20chain%20reaction%20and%20melting%20curve%20analysis%2C%20using%20specific%20gene%20primers%20and%20probes.%20Patients%20were%20subdivided%20into%20group%20A%20%28G%5C%2FA%20genotype%29%20and%20group%20G%20%28G%5C%2FG%20genotype%29.%20We%20compared%20clinical%20responses%20to%20etanercept%20between%20groups%20A%20and%20G%20after%206%20months%2C%20using%20the%20Disease%20Activity%20Score%20in%2028%20joints%20%28DAS28%29.%20After%2012-month%20treatment%2C%2048%20of%2086%20patients%20were%20evaluated%20again.%5CnRESULTS%3A%20Of%2086%20patients%2C%2018%20%2821%25%29%20belonged%20in%20group%20A%20and%2068%20%2879%25%29%20belonged%20in%20group%20G.%20After%206-month%20treatment%2C%2055.6%25%20of%20patients%20in%20group%20A%20and%2082.4%25%20of%20patients%20in%20group%20G%20had%20DAS28%20improvement%20%26gt%3B1.2%20%28P%20%3D%200.027%20by%20chi-square%29.%20The%20mean%20%2B%5C%2F-%20SD%20DAS28%20improvement%20was%201.69%20%2B%5C%2F-%201.31%20in%20group%20A%20and%202.23%20%2B%5C%2F-%201.19%20in%20group%20G%20%28P%20%3D%200.098%20by%20t-test%29.%20After%201-year%20treatment%2048%20patients%20were%20tested%20again%3A%2010%20%2821%25%29%20belonged%20in%20group%20A%20and%2038%20%2879%25%29%20belonged%20in%20group%20G.%20Forty%20percent%20of%20patients%20in%20group%20A%20and%2087%25%20in%20group%20G%20had%20DAS28%20improvement%20%26gt%3B1.2%20%28P%20%3D%200.005%20by%20chi-square%29.%20The%20mean%20%2B%5C%2F-%20SD%20DAS28%20improvement%20was%201.334%20%2B%5C%2F-%201.37%20in%20group%20A%20and%202.29%20%2B%5C%2F-%201.47%20in%20group%20G%20%28Mann-Whitney%20U%20test%20%3D%20115%2C%20P%20%3D%200.0057%29.%5CnCONCLUSION%3A%20RA%20patients%20with%20a%20-308%20G%5C%2FG%20TNFalpha%20genotype%20respond%20to%20etanercept%20better%20than%20patients%20with%20a%20-308%20A%5C%2FG%20genotype.%22%2C%22date%22%3A%22Dec%2015%2C%202007%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fart.23092%22%2C%22ISSN%22%3A%220004-3591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22ZHG2SSF5%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Auger%20et%20al.%22%2C%22parsedDate%22%3A%222007-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAuger%2C%20I.%2C%20Roudier%2C%20C.%2C%20Guis%2C%20S.%2C%20Balandraud%2C%20N.%20and%20Roudier%2C%20J.%20%282007%29%20%26%23x201C%3BHLA-DRB1%2A0404%20is%20strongly%20associated%20with%20anticalpastatin%20antibodies%20in%20rheumatoid%20arthritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20the%20Rheumatic%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2C%2066%2812%29%2C%20pp.%201588%26%23x2013%3B1593.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fard.2006.067231%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fard.2006.067231%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HLA-DRB1%2A0404%20is%20strongly%20associated%20with%20anticalpastatin%20antibodies%20in%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20test%20whether%20HLA-DR%20alleles%20influence%20the%20production%20of%20particular%20autoantibodies%20in%20rheumatoid%20arthritis%20%28RA%29%20patients%2C%20we%20screened%20synovial%20proteins%20with%20sera%20of%20RA%20patients%20homozygous%20for%20different%20HLA-DR%20alleles%20by%20using%202D%20blots.%20We%20found%20that%20sera%20of%20RA%20patients%20homozygous%20for%20HLA-DRB1%2A0404%20recognised%20a%20100-kDa%20synovial%20protein%20identified%20as%20calpastatin.%20We%20studied%20B%20and%20T%20cell%20epitopes%20on%20calpastatin%20and%20their%20association%20with%20HLA-DRB1%2A0404.%5CnMETHODS%3A%20The%20frequency%20of%20positive%20sera%20in%20patients%20expressing%20different%20RA-associated%20HLA-DR%20allele%20combinations%20was%20calculated%20by%20inhouse%20ELISA%20using%20purified%20synovial%20calpastatin%20or%20calpastatin%20peptides%20encompassing%20the%20entire%20calpastatin%20protein%20as%20immunosorbent.%20Interaction%20between%20calpastatin%20peptides%20and%20HLA-DR%20alleles%20was%20tested%20by%20a%20direct%20binding%20assay.%20T%20cell%20responses%20to%20calpastatin%20were%20measured%20in%20RA%20patients%20and%20controls.%5CnRESULTS%3A%20We%20found%20that%20RA-associated%20HLA-DR%20alleles%20are%20associated%20with%20presence%20of%20autoantibodies%20to%20synovial%20calpastatin%20in%20RA%20patients%26%23039%3B%20sera.%20HLA-DRB1%2A0404%20is%20strongly%20associated%20with%20antisynovial%20calpastatin%20in%20RA%20sera.%20One%20linear%20B%20cell%20epitope%20is%20preferentially%20associated%20with%20HLA-DRB1%2A0404.%20Multiple%20peptides%20from%20calpastatin%20bind%20every%20tested%20HLA-DR%20allele%20associated%20or%20not%20with%20RA.%20Peptides%20from%20domain%201%20and%204%20of%20calpastatin%20are%20the%20best%20HLA-DR%20allele%20binders.%20The%20T%20cell%20response%20to%20calpastatin%20is%20frequent%20in%20RA%20patients%20and%20independent%20of%20the%20HLA-DR%20background.%5CnCONCLUSIONS%3A%20HLA-DRB1%2A0404%20is%20strongly%20associated%20with%20anticalpastatin%20antibodies%20in%20rheumatoid%20arthritis.%22%2C%22date%22%3A%22Dec%202007%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fard.2006.067231%22%2C%22ISSN%22%3A%221468-2060%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A44Z%22%7D%7D%2C%7B%22key%22%3A%227D2GUNBC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guis%20and%20Pellissier%22%2C%22parsedDate%22%3A%222007-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuis%2C%20S.%20and%20Pellissier%2C%20J.F.%20%282007%29%20%26%23x201C%3B%5BForeword%20-%20macrophage%20mediated%20myofasciites%5D%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BRevue%20Neurologique%26lt%3B%5C%2Fi%26gt%3B%2C%20163%2810%29%2C%20pp.%20979%26%23x2013%3B980.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BForeword%20-%20macrophage%20mediated%20myofasciites%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20F.%22%2C%22lastName%22%3A%22Pellissier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Oct%202007%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220035-3787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22X2B8734P%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Balandraud%20et%20al.%22%2C%22parsedDate%22%3A%222007-06-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBalandraud%2C%20N.%2C%20Guis%2C%20S.%2C%20Meynard%2C%20J.B.%2C%20Auger%2C%20I.%2C%20Roudier%2C%20J.%20and%20Roudier%2C%20C.%20%282007%29%20%26%23x201C%3BLong-term%20treatment%20with%20methotrexate%20or%20tumor%20necrosis%20factor%20alpha%20inhibitors%20does%20not%20increase%20epstein-barr%20virus%20load%20in%20patients%20with%20rheumatoid%20arthritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BArthritis%20and%20Rheumatism%26lt%3B%5C%2Fi%26gt%3B%2C%2057%285%29%2C%20pp.%20762%26%23x2013%3B767.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.22783%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.22783%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20treatment%20with%20methotrexate%20or%20tumor%20necrosis%20factor%20alpha%20inhibitors%20does%20not%20increase%20epstein-barr%20virus%20load%20in%20patients%20with%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Baptiste%22%2C%22lastName%22%3A%22Meynard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Roudier%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20We%20previously%20demonstrated%20that%20patients%20with%20rheumatoid%20arthritis%20%28RA%29%20have%20a%2010-fold%20systemic%20Epstein-Barr%20virus%20%28EBV%29%20overload%2C%20very%20similar%20to%20that%20observed%20in%20healthy%20organ%20transplant%20recipients.%20Our%20objective%20was%20to%20monitor%20EBV%20load%20over%20time%20in%20patients%20with%20RA%20receiving%20methotrexate%2C%20infliximab%2C%20or%20etanercept%20to%20detect%20possible%20immunosuppression-associated%20EBV%20dysregulation%2C%20as%20described%20in%20posttransplant%20lymphoproliferative%20disease.%5CnMETHODS%3A%20The%20EBV%20load%20in%20the%20peripheral%20blood%20mononuclear%20cells%20%28PBMCs%29%20from%2019%20patients%20receiving%20methotrexate%2C%2068%20patients%20receiving%20infliximab%2C%20and%2048%20patients%20receiving%20etanercept%20was%20monitored%20for%20durations%20ranging%20from%206%20months%20to%205%20years%20using%20a%20real-time%20polymerase%20chain%20reaction%20assay%20previously%20developed%20for%20that%20purpose.%20The%20effect%20of%20treatment%20duration%20on%20EBV%20load%20and%20the%20link%20between%20the%20Disease%20Activity%20Score%20in%2028%20joints%20and%20EBV%20load%20were%20analyzed%20by%20generalized%20estimating%20equations.%5CnRESULTS%3A%20Methotrexate%20tended%20to%20decrease%20EBV%20load%20over%20time%2C%20but%20this%20did%20not%20reach%20significance.%20Tumor%20necrosis%20factor%20alpha%20%28TNFalpha%29%20inhibitors%20did%20not%20significantly%20modify%20EBV%20load%20over%20time.%20Finally%2C%20high%20disease%20activity%20was%20significantly%20associated%20with%20high%20EBV%20load.%5CnCONCLUSION%3A%20Long-term%20usage%20of%20methotrexate%20or%20TNFalpha%20inhibitors%20in%20patients%20with%20RA%20does%20not%20significantly%20influence%20EBV%20load%20in%20PBMCs.%22%2C%22date%22%3A%22Jun%2015%2C%202007%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fart.22783%22%2C%22ISSN%22%3A%220004-3591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A46Z%22%7D%7D%2C%7B%22key%22%3A%227KMSB7IG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Charpin%20et%20al.%22%2C%22parsedDate%22%3A%222007-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCharpin%2C%20C.%2C%20Berbis%2C%20P.%2C%20Schmitz%2C%20J.%2C%20Boudinet%2C%20H.%2C%20Mattei%2C%20J.-P.%2C%20Balandraud%2C%20N.%2C%20Chagnaud%2C%20C.%2C%20Roudier%2C%20J.%20and%20Guis%2C%20S.%20%282007%29%20%26%23x201C%3BNeurofibromatosis%20type%201%20with%20sciatica%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%2C%20Bone%2C%20Spine%3A%20Revue%20Du%20Rhumatisme%26lt%3B%5C%2Fi%26gt%3B%2C%2074%283%29%2C%20pp.%20300%26%23x2013%3B301.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2006.09.013%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2006.09.013%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neurofibromatosis%20type%201%20with%20sciatica%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Charpin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Berbis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22Schmitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Boudinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22May%202007%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2006.09.013%22%2C%22ISSN%22%3A%221778-7254%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22QR3NGWRX%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Mattei%20et%20al.%22%2C%22parsedDate%22%3A%222006-11%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMattei%2C%20J.P.%2C%20Fur%2C%20Y.L.%2C%20Cuge%2C%20N.%2C%20Guis%2C%20S.%2C%20Cozzone%2C%20P.J.%20and%20Bendahan%2C%20D.%20%282006%29%20%26%23x201C%3BSegmentation%20of%20fascias%2C%20fat%20and%20muscle%20from%20magnetic%20resonance%20images%20in%20humans%3A%20the%20DISPIMAG%20software%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMagma%20%28New%20York%2C%20N.Y.%29%26lt%3B%5C%2Fi%26gt%3B%2C%2019%285%29%2C%20pp.%20275%26%23x2013%3B279.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10334-006-0051-1%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10334-006-0051-1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Segmentation%20of%20fascias%2C%20fat%20and%20muscle%20from%20magnetic%20resonance%20images%20in%20humans%3A%20the%20DISPIMAG%20software%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20P%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%20Le%22%2C%22lastName%22%3A%22Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Cuge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20J%22%2C%22lastName%22%3A%22Cozzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22Segmentation%20of%20human%20limb%20MR%20images%20into%20muscle%2C%20fat%20and%20fascias%20remains%20a%20cumbersome%20task.%20We%20have%20developed%20a%20new%20software%20%28DISPIMAG%29%20that%20allows%20automatic%20and%20highly%20reproducible%20segmentation%20of%20lower-limb%20MR%20images.%20Based%20on%20a%20pixel%20intensity%20analysis%2C%20this%20software%20does%20not%20need%20any%20previous%20mathematical%20or%20statistical%20assumptions.%20It%20displays%20a%20histogram%20with%20two%20main%20signals%20corresponding%20to%20fat%20and%20muscle%2C%20and%20permits%20an%20accurate%20quantification%20of%20their%20relative%20spatial%20distribution.%20To%20allow%20a%20systematic%20discrimination%20between%20muscle%20and%20fat%20in%20any%20subject%2C%20fixed%20boundaries%20were%20first%20determined%20manually%20in%20a%20group%20of%2024%20patients.%20Secondly%2C%20an%20entirely%20automatic%20process%20using%20these%20boundaries%20was%20tested%20by%20three%20operators%20on%20four%20patients%20and%20compared%20to%20the%20manual%20approach%2C%20showing%20a%20high%20concordance.%22%2C%22date%22%3A%22Nov%202006%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10334-006-0051-1%22%2C%22ISSN%22%3A%220968-5243%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SVI8UJ6H%22%2C%22NW6SZQBR%22%2C%224ZGX55W3%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222023-05-15T08%3A59%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22V7NZTIR4%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Guis%20et%20al.%22%2C%22parsedDate%22%3A%222006-08-15%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuis%2C%20S.%2C%20Figarella-Branger%2C%20D.%2C%20Mattei%2C%20J.P.%2C%20Nicoli%2C%20F.%2C%20Le%20Fur%2C%20Y.%2C%20Kozak-Ribbens%2C%20G.%2C%20Pellissier%2C%20J.F.%2C%20Cozzone%2C%20P.J.%2C%20Amabile%2C%20N.%20and%20Bendahan%2C%20D.%20%282006%29%20%26%23x201C%3BIn%20vivo%20and%20in%20vitro%20characterization%20of%20skeletal%20muscle%20metabolism%20in%20patients%20with%20statin-induced%20adverse%20effects%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BArthritis%20and%20rheumatism%26lt%3B%5C%2Fi%26gt%3B%2C%2055%284%29%2C%20pp.%20551%26%23x2013%3B557.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.22100%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.22100%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22In%20vivo%20and%20in%20vitro%20characterization%20of%20skeletal%20muscle%20metabolism%20in%20patients%20with%20statin-induced%20adverse%20effects%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20P%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Nicoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Le%20Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Kozak-Ribbens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20F%22%2C%22lastName%22%3A%22Pellissier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20J%22%2C%22lastName%22%3A%22Cozzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Amabile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Statins%20%283-hydroxymethylglutaryl-coenzyme%20A%20reductase%20inhibitor%29%20are%20widely%20used%20to%20treat%20hypercholesterolemia.%20They%20are%20generally%20well%20tolerated%2C%20but%20myotoxic%20effects%20have%20been%20reported%20and%20the%20corresponding%20mechanisms%20are%20still%20a%20matter%20of%20debate.%20The%20aim%20of%20the%20present%20study%20was%20to%20determine%20whether%20impairment%20of%20calcium%20homeostasis%20and%5C%2For%20mitochondrial%20impairment%20could%20account%20for%20the%20adverse%20effects%20of%20statins%20in%20skeletal%20muscle.%5CnMETHODS%3A%20Eleven%20patients%20with%20increased%20creatine%20kinase%20levels%20and%20myalgias%20after%20statin%20treatment%20were%20evaluated%20using%20in%20vitro%20contracture%20tests%20%28IVCTs%29%2C%20histology%2C%20and%2031P%20magnetic%20resonance%20spectroscopy%20%2831P-MRS%29.%5CnRESULTS%3A%20IVCT%20results%20were%20abnormal%20in%207%20of%20the%209%20patients%2C%20indicating%20an%20impaired%20calcium%20homeostasis.%20The%2031P-MRS%20investigation%20disclosed%20no%20anomaly%20at%20rest%2C%20and%20the%20aerobic%20function%20assessed%20during%20the%20postexercise%20recovery%20period%20was%20normal.%20On%20the%20contrary%2C%20the%20pH%20recovery%20kinetics%20was%20significantly%20slowed%20down%20as%20indicated%20by%20a%20reduced%20proton%20efflux%2C%20which%20could%20be%20ultimately%20linked%20to%20a%20failure%20of%20calcium%20homeostasis.%20Overall%2C%20our%20observations%20indicate%20a%20normal%20mitochondrial%20function%20and%20raise%20the%20possibility%20that%20statins%20may%20unmask%20a%20latent%20pathology%20involving%20an%20impairment%20of%20calcium%20homeostasis%20such%20as%20malignant%20hyperthermia%20%28MH%29.%5CnCONCLUSION%3A%20In%20case%20of%20susceptibility%20to%20MH%2C%20statins%20treatment%20must%20be%20administered%20with%20caution%2C%20and%20signs%20of%20adverse%20effects%20should%20be%20checked.%22%2C%22date%22%3A%22Aug%2015%2C%202006%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fart.22100%22%2C%22ISSN%22%3A%220004-3591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SVI8UJ6H%22%2C%22NW6SZQBR%22%2C%224ZGX55W3%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A16%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22SPRU6QFE%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Figarella-Branger%20et%20al.%22%2C%22parsedDate%22%3A%222006-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFigarella-Branger%2C%20D.%2C%20Schleinitz%2C%20N.%2C%20Bouti%26%23xE8%3Bre-Alban%26%23xE8%3Bse%2C%20B.%2C%20Camoin%2C%20L.%2C%20Bardin%2C%20N.%2C%20Guis%2C%20S.%2C%20Pouget%2C%20J.%2C%20Cognet%2C%20C.%2C%20Pellissier%2C%20J.-F.%20and%20Dignat-George%2C%20F.%20%282006%29%20%26%23x201C%3BPlatelet-endothelial%20cell%20adhesion%20molecule-1%20and%20CD146%3A%20soluble%20levels%20and%20in%20situ%20expression%20of%20cellular%20adhesion%20molecules%20implicated%20in%20the%20cohesion%20of%20endothelial%20cells%20in%20idiopathic%20inflammatory%20myopathies%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Journal%20of%20Rheumatology%26lt%3B%5C%2Fi%26gt%3B%2C%2033%288%29%2C%20pp.%201623%26%23x2013%3B1630.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Platelet-endothelial%20cell%20adhesion%20molecule-1%20and%20CD146%3A%20soluble%20levels%20and%20in%20situ%20expression%20of%20cellular%20adhesion%20molecules%20implicated%20in%20the%20cohesion%20of%20endothelial%20cells%20in%20idiopathic%20inflammatory%20myopathies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Schleinitz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re-Alban%5Cu00e8se%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Camoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Bardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pouget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Cognet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Pellissier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Dignat-George%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Idiopathic%20inflammatory%20myopathies%20%28IIM%29%20are%20a%20heterogeneous%20group%20of%20diseases%20characterized%20by%20chronic%20inflammation%20of%20muscles.%20We%20investigated%20the%20role%20of%20cellular%20adhesion%20molecules%20implicated%20in%20the%20cohesion%20of%20endothelial%20cells%20in%20IIM.%5CnMETHODS%3A%20In%2022%20patients%20with%20IIM%20we%20investigated%20plasma%20concentrations%20of%20soluble%20junctional%20adhesion%20molecules%20%5Bplatelet-endothelial%20cell%20adhesion%20molecule%20%28sPECAM-1%29%20and%20sCD146%5D%20and%20cellular%20adhesion%20molecules%20%5BsP-selectin%2C%20sE-selectin%2C%20intercellular%20adhesion%20molecule%20%28sICAM-1%29%2C%20and%20vascular%20cell%20adhesion%20molecule%20%28sVCAM-1%29%5D%20implicated%20in%20leukocyte%5C%2Fendothelial%20cell%20interactions.%20Results%20were%20compared%20to%20a%20control%20group.%20Muscle%20biopsy%20samples%20from%208%20out%20of%2022%20IIM%20patients%20were%20studied%20by%20immunohistochemistry%20for%20tissue%20expression%20of%20these%20molecules%20and%20compared%20to%20normal%20muscle%20samples.%20PECAM-1%20and%20CD146%20expression%20was%20also%20studied%20using%20immunoblots%20from%20muscle%20biopsies%20from%205%20patients%20and%202%20controls.%5CnRESULTS%3A%20We%20observed%20distinct%20patterns%20of%20soluble%20levels%20and%20in%20situ%20expression%20between%20dermatomyositis%20%28DM%29%2C%20polymyositis%20%28PM%29%2C%20and%20sporadic%20inclusion%20body%20myositis%20%28s-IBM%29.%20PM%20samples%20showed%20significantly%20increased%20levels%20of%20sCD146%2C%20sPECAM-1%2C%20and%20s-ICAM1%20and%20increased%20expression%20of%20CD146%2C%20CD31%2C%20and%20ICAM-1%20in%20endothelial%20cells%2C%20whereas%20CD146%20and%20ICAM-1%20were%20also%20recorded%20in%20some%20muscle%20fibers.%20In%20DM%2C%20sE-selectin%2C%20sP-selectin%2C%20and%20sPECAM-1%20were%20significantly%20increased%2C%20with%20abnormal%20expression%20of%20ICAM-1%20in%20endothelial%20cells%20and%20perifascicular%20muscle%20fibers.%20In%20the%20small%20group%20of%20s-IBM%20samples%2C%20results%20were%20similar%20to%20PM%2C%20but%20the%20only%20significant%20increase%20was%20the%20level%20of%20sPECAM-1.%20Immunoblots%20confirmed%20increased%20expression%20of%20PECAM-1%20and%20CD146%20in%20all%20IIM%20muscles%20in%20comparison%20to%20controls%2C%20with%20the%20highest%20expression%20in%20PM%20and%20IBM%20samples.%5CnCONCLUSION%3A%20We%20observed%20abnormal%20increases%20of%20soluble%20levels%20of%20adhesion%20molecules%20implicated%20in%20endothelial%20cell%20junctions%20in%20PM%20%28sCD146%2C%20sPECAM-1%29%20and%20to%20a%20lesser%20extent%20in%20DM%20and%20s-IBM%20%28sPECAM-1%29.%20We%20conclude%20that%20the%20distinctly%20different%20profiles%20between%20PM%5C%2Fs-IBM%20and%20DM%20reflect%20differences%20in%20the%20pathophysiological%20background%20of%20these%20diseases.%22%2C%22date%22%3A%22Aug%202006%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220315-162X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22BC8D887Q%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Bendahan%20et%20al.%22%2C%22parsedDate%22%3A%222006-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBendahan%2C%20D.%2C%20Mattei%2C%20J.P.%2C%20Guis%2C%20S.%2C%20Kozak-Ribbens%2C%20G.%20and%20Cozzone%2C%20P.J.%20%282006%29%20%26%23x201C%3B%5BNon-invasive%20investigation%20of%20muscle%20function%20using%2031P%20magnetic%20resonance%20spectroscopy%20and%201H%20MR%20imaging%5D%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BRevue%20neurologique%26lt%3B%5C%2Fi%26gt%3B%2C%20162%284%29%2C%20pp.%20467%26%23x2013%3B484.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BNon-invasive%20investigation%20of%20muscle%20function%20using%2031P%20magnetic%20resonance%20spectroscopy%20and%201H%20MR%20imaging%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20P%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Kozak-Ribbens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20J%22%2C%22lastName%22%3A%22Cozzone%22%7D%5D%2C%22abstractNote%22%3A%2231P%20MRS%20and%201H%20MRI%20of%20skeletal%20muscle%20have%20become%20major%20new%20tools%20allowing%20a%20complete%20non%20invasive%20investigation%20of%20muscle%20function%20both%20in%20the%20clinical%20setting%20and%20in%20basic%20research.%20The%20comparative%20analysis%20of%20normal%20and%20diseased%20muscle%20remains%20a%20major%20requirement%20to%20further%20define%20metabolic%20events%20surrounding%20muscle%20contraction%20and%20the%20metabolic%20anomalies%20underlying%20pathologies.%20Also%2C%20standardized%20rest-exercise-recovery%20protocols%20for%20the%20exploration%20of%20muscle%20metabolism%20by%20P-31%20MRS%20in%20healthy%20volunteers%20as%20well%20as%20in%20patients%20with%20intolerance%20to%20exercise%20have%20been%20developed.%20The%20CRMBM%20protocol%20is%20based%20on%20a%20short-term%20intense%20exercise%2C%20which%20is%20very%20informative%20and%20well%20accepted%20by%20volunteers%20and%20patients.%20Invariant%20metabolic%20parameters%20have%20been%20defined%20to%20characterize%20the%20normal%20metabolic%20response%20to%20the%20protocol.%20Deviations%20from%20normality%20can%20be%20directly%20interpreted%20in%20terms%20of%20specific%20pathologies%20in%20some%20favorable%20cases.%20This%20protocol%20has%20been%20applied%20to%20more%20than%204%2C000%20patients%20and%20healthy%20volunteers%20over%20a%20period%20of%2015%20years.%20On%20the%20other%20hand%2C%20MRI%20investigations%20provide%20anatomical%20and%20functional%20information%20from%20resting%20and%20exercising%20muscle.%20From%20a%20diagnostic%20point%20of%20view%2C%20dedicated%20pulse%20sequences%20can%20be%20used%20in%20order%20to%20detect%20and%20quantify%20muscle%20inflammation%2C%20fatty%20replacement%2C%20muscle%20hyper%20and%20hypotrophy.%20In%20most%20cases%2C%20MR%20techniques%20provide%20valuable%20information%20which%20has%20to%20be%20processed%20in%20conjunction%20with%20traditional%20invasive%20biochemical%2C%20electrophysiological%20and%20histoenzymological%20tests.%20P-31%20MRS%20has%20proved%20particularly%20useful%20in%20the%20therapeutic%20follow-up%20of%20palliative%20therapies%20%28coenzyme%20Q%20treatment%20of%20mitochondriopathies%29%20and%20in%20family%20investigations.%20It%20is%20now%20an%20accepted%20diagnostic%20tool%20in%20the%20array%20of%20tests%20which%20are%20used%20to%20characterize%20muscle%20disorders%20in%20clinical%20routine.%20As%20a%20research%20tool%2C%20it%20will%20keep%20bringing%20new%20information%20on%20the%20physiopathology%20of%20muscle%20diseases%20in%20animal%20models%20and%20in%20humans%20and%20should%20play%20a%20role%20in%20the%20metabolic%20characterization%20of%20gene%20and%20cell%20therapy.%22%2C%22date%22%3A%22Apr%202006%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220035-3787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%224ZGX55W3%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A16%3A14Z%22%7D%7D%2C%7B%22key%22%3A%2242FDA2H4%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alcaraz%20et%20al.%22%2C%22parsedDate%22%3A%222006-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAlcaraz%2C%20P.%2C%20Aubran%2C%20C.%2C%20Jaoua%2C%20S.%2C%20Roudier%2C%20C.%2C%20Mattei%2C%20J.P.%2C%20Announ%2C%20N.%2C%20Chagnaud%2C%20C.%2C%20Roudier%2C%20J.%20and%20Guis%2C%20S.%20%282006%29%20%26%23x201C%3BCalcaneal%20osteomyelitis%20due%20to%20fistulization%20of%20an%20ulcerated%20rheumatoid%20nodule%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%2C%20Bone%2C%20Spine%3A%20Revue%20Du%20Rhumatisme%26lt%3B%5C%2Fi%26gt%3B%2C%2073%281%29%2C%20pp.%20102%26%23x2013%3B104.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2005.01.006%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2005.01.006%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Calcaneal%20osteomyelitis%20due%20to%20fistulization%20of%20an%20ulcerated%20rheumatoid%20nodule%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Alcaraz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Aubran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sami%22%2C%22lastName%22%3A%22Jaoua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Announ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Chagnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%5D%2C%22abstractNote%22%3A%22Calcaneal%20osteomyelitis%20is%20uncommon%20and%20difficult%20to%20treat.%20Cases%20due%20to%20fistulization%20of%20an%20infected%20rheumatoid%20nodule%20are%20exceedingly%20rare.%5CnPATIENT%3A%20A%2065-year-old%20patient%20with%20nodular%20rheumatoid%20arthritis%20%28RA%29%20experienced%20osteomyelitis%20of%20the%20left%20calcaneus%20due%20to%20inoculation%20from%20a%20fistula%20draining%20an%20ulcerated%20rheumatoid%20nodule.%20Pseudomonas%20aeruginosa%20and%20Enterobacter%20cloacae%20were%20recovered.%20The%20conventional%20treatment%20of%20calcaneal%20osteomyelitis%20relies%20on%20antibiotics%20and%20calcanectomy%20or%20foot%20amputation.%20We%20used%20two%20appropriate%20antibiotics%20and%20monthly%20intravenous%20injections%20of%2090%20mg%20of%20pamidronate.%5CnRESULT%3A%20One%20year%20into%20treatment%2C%20the%20patient%20was%20free%20of%20pain%20and%20the%20skin%20wound%20was%20fully%20healed.%20On%20a%20follow-up%20computed%20tomography%20%28CT%29%20scan%2C%20the%20fistulous%20tract%20was%20seen%20to%20be%20closed%20and%20the%20large%20calcaneal%20defect%20almost%20completely%20filled%20with%20new%20bone.%5CnCONCLUSION%3A%20Combining%20two%20antibiotics%20and%20pamidronate%20may%20be%20a%20viable%20alternative%20to%20excision%20surgery%20or%20amputation%20in%20some%20patients%20with%20bone%20infection%20carrying%20a%20risk%20of%20fracture.%22%2C%22date%22%3A%22Jan%202006%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2005.01.006%22%2C%22ISSN%22%3A%221297-319X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A23Z%22%7D%7D%2C%7B%22key%22%3A%224EP6AWJI%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Auger%20et%20al.%22%2C%22parsedDate%22%3A%222005-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAuger%2C%20I.%2C%20Sebbag%2C%20M.%2C%20Vincent%2C%20C.%2C%20Balandraud%2C%20N.%2C%20Guis%2C%20S.%2C%20Nogueira%2C%20L.%2C%20Svensson%2C%20B.%2C%20Cantagrel%2C%20A.%2C%20Serre%2C%20G.%20and%20Roudier%2C%20J.%20%282005%29%20%26%23x201C%3BInfluence%20of%20HLA-DR%20genes%20on%20the%20production%20of%20rheumatoid%20arthritis-specific%20autoantibodies%20to%20citrullinated%20fibrinogen%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BArthritis%20and%20Rheumatism%26lt%3B%5C%2Fi%26gt%3B%2C%2052%2811%29%2C%20pp.%203424%26%23x2013%3B3432.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.21391%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fart.21391%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Influence%20of%20HLA-DR%20genes%20on%20the%20production%20of%20rheumatoid%20arthritis-specific%20autoantibodies%20to%20citrullinated%20fibrinogen%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Auger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mireille%22%2C%22lastName%22%3A%22Sebbag%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Vincent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Balandraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonor%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bj%5Cu00f6rn%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Cantagrel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Serre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Antibodies%20directed%20against%20citrullinated%20fibrinogen%20are%20highly%20specific%20for%20rheumatoid%20arthritis%20%28RA%29.%20This%20study%20was%20undertaken%20to%20test%20whether%20RA-associated%20HLA-DR%20alleles%20are%20associated%20with%20anti-citrullinated%20fibrinogen%20in%20RA%20patient%20sera%20and%20whether%20replacement%20of%20arginyl%20by%20citrullyl%20residues%20on%20fibrinogen%20peptides%20modifies%20their%20binding%20to%20HLA-DR%20molecules%20and%20their%20recognition%20by%20T%20cells.%5CnMETHODS%3A%20Antikeratin%2C%20antifilaggrin%2C%20and%20anti-citrullinated%20fibrinogen%20antibodies%20were%20assayed%20in%20RA%20patients%20who%20had%20undergone%20HLA-DR%20typing.%20Direct%20assays%20were%20performed%20to%20investigate%20binding%20of%20citrullinated%20or%20native%20fibrinogen%20peptides%20%28encompassing%20the%20entire%20alpha-%20and%20beta-chains%20of%20fibrinogen%29%20to%20purified%20HLA-DR%20molecules.%20T%20cell%20proliferative%20responses%20to%20citrullinated%20or%20native%20fibrinogen%20peptides%20were%20measured%20in%20RA%20patients%20and%20controls.%5CnRESULTS%3A%20HLA-DRB1%2A0404%20was%20associated%20with%20anti-citrullinated%20fibrinogen%20in%20RA%20sera%20%28P%20%3D%200.002%29.%20For%20the%20RA-associated%20alleles%20HLA-DRB1%2A0401%20and%20HLA-DR1%2C%20there%20was%20a%20nonsignificant%20trend%20toward%20association%20%28P%20%3D%200.07%29.%20Multiple%20peptides%20from%20the%20alpha-%20and%20beta-chains%20of%20fibrinogen%20bound%20many%20HLA-DR%20alleles%3B%20DRB1%2A0404%20was%20the%20best%20fibrinogen%20peptide%20binder.%20Citrullination%20did%20not%20influence%20fibrinogen%20peptide%20binding%20to%20HLA-DR%20or%20fibrinogen%20peptide%20recognition%20by%20T%20cells.%20Peripheral%20blood%20T%20cells%20that%20recognized%20native%20or%20citrullinated%20fibrinogen%20peptides%20were%20common%20in%20RA%20patients%20but%20not%20in%20healthy%20controls.%5CnCONCLUSION%3A%20The%20RA-associated%20HLA-DRB1%2A0404%20allele%20is%20also%20associated%20with%20production%20of%20antibodies%20to%20citrullinated%20fibrinogen.%20DRB1%2A0401%20and%20DRB1%2A01%20tend%20to%20be%20associated%20with%20anti-citrullinated%20fibrinogen%2C%20but%20this%20is%20not%20statistically%20significant.%20Citrullination%20of%20fibrinogen%20peptide%20does%20not%20influence%20peptide-DR-T%20cell%20interaction.%20Finally%2C%20T%20cell%20proliferation%20in%20response%20to%20citrullinated%20or%20uncitrullinated%20fibrinogen%20peptides%20is%20frequent%20in%20RA%20patients%20and%20very%20infrequent%20in%20controls.%22%2C%22date%22%3A%22Nov%202005%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fart.21391%22%2C%22ISSN%22%3A%220004-3591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22DUG4Z69R%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Guis%20et%20al.%22%2C%22parsedDate%22%3A%222005-10%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuis%2C%20S.%2C%20Mattei%2C%20J.-P.%2C%20Cozzone%2C%20P.J.%20and%20Bendahan%2C%20D.%20%282005%29%20%26%23x201C%3BPathophysiology%20and%20clinical%20presentations%20of%20rhabdomyolysis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%2C%20bone%2C%20spine%3A%20revue%20du%20rhumatisme%26lt%3B%5C%2Fi%26gt%3B%2C%2072%285%29%2C%20pp.%20382%26%23x2013%3B391.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2004.04.010%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2004.04.010%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pathophysiology%20and%20clinical%20presentations%20of%20rhabdomyolysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20J%22%2C%22lastName%22%3A%22Cozzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22Rhabdomyolysis%20has%20sparked%20new%20interest%20in%20recent%20years.%20The%20causes%20of%20rhabdomyolysis%20include%20drugs%20and%20other%20toxic%20agents%2C%20infections%2C%20physical%20exertion%2C%20crush%20injury%2C%20and%20muscle%20diseases%20%28dystrophinopathies%20and%20metabolic%20myopathies%29.%20Prompt%20identification%20of%20the%20pathophysiological%20mechanism%20is%20the%20key%20to%20rapid%20control%20of%20the%20acute%20episode%20and%20to%20prevention%20of%20recurrences.%20In%20this%20update%2C%20we%20discuss%20the%20pathophysiological%20mechanisms%20and%20nosology%20of%20rhabdomyolysis%2C%20as%20well%20as%20diagnostic%20investigations%2C%20with%20special%20emphasis%20on%20noninvasive%20methods.%22%2C%22date%22%3A%22Oct%202005%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2004.04.010%22%2C%22ISSN%22%3A%221297-319X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%224ZGX55W3%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A16%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22G89QFHN6%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Poullin%20et%20al.%22%2C%22parsedDate%22%3A%222005-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPoullin%2C%20P.%2C%20Announ%2C%20N.%2C%20Mugnier%2C%20B.%2C%20Guis%2C%20S.%2C%20Roudier%2C%20J.%20and%20Lef%26%23xE8%3Bvre%2C%20P.%20%282005%29%20%26%23x201C%3BProtein%20A-immunoadsorption%20%28Prosorba%20column%29%20in%20the%20treatment%20of%20rheumatoid%20arthritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJoint%2C%20Bone%2C%20Spine%3A%20Revue%20Du%20Rhumatisme%26lt%3B%5C%2Fi%26gt%3B%2C%2072%282%29%2C%20pp.%20101%26%23x2013%3B103.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2004.02.009%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jbspin.2004.02.009%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Protein%20A-immunoadsorption%20%28Prosorba%20column%29%20in%20the%20treatment%20of%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Poullin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Announ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Mugnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Roudier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Lef%5Cu00e8vre%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Mar%202005%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jbspin.2004.02.009%22%2C%22ISSN%22%3A%221297-319X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A15%3A23Z%22%7D%7D%2C%7B%22key%22%3A%229RUBRNJF%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Guis%20et%20al.%22%2C%22parsedDate%22%3A%222004-11%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuis%2C%20S.%2C%20Mattei%2C%20J.-P.%2C%20Pellissier%2C%20J.-F.%2C%20Nicoli%2C%20F.%2C%20Figarella-Branger%2C%20D.%2C%20Le%20Fur%2C%20Y.%2C%20Kaplanski%2C%20G.%2C%20Pelletier%2C%20J.%2C%20Harle%2C%20J.-R.%2C%20Cozzone%2C%20P.J.%20and%20Bendahan%2C%20D.%20%282004%29%20%26%23x201C%3BMRI%20and%2031PMR%20spectroscopy%20investigations%20of%20muscle%20function%20disclose%20no%20abnormality%20in%20macrophagic%20myofasciitis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Journal%20of%20rheumatology%26lt%3B%5C%2Fi%26gt%3B%2C%2031%2811%29%2C%20pp.%202313%26%23x2013%3B2314.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22MRI%20and%2031PMR%20spectroscopy%20investigations%20of%20muscle%20function%20disclose%20no%20abnormality%20in%20macrophagic%20myofasciitis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Pellissier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Nicoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Figarella-Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Le%20Fur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Kaplanski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Robert%22%2C%22lastName%22%3A%22Harle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20J%22%2C%22lastName%22%3A%22Cozzone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Nov%202004%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%220315-162X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22SVI8UJ6H%22%2C%22NW6SZQBR%22%2C%224ZGX55W3%22%2C%22B4EWFM7E%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222015-09-04T09%3A16%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22HUMQKS45%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A1497928%2C%22username%22%3A%22fkober%22%2C%22name%22%3A%22Frank%20Kober%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Ffkober%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Bendahan%20et%20al.%22%2C%22parsedDate%22%3A%222004-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBendahan%2C%20D.%2C%20Guis%2C%20S.%2C%20Monnier%2C%20N.%2C%20Kozak-Ribbens%2C%20G.%2C%20Lunardi%2C%20J.%2C%20Ghattas%2C%20B.%2C%20Mattei%2C%20J.-P.%20and%20Cozzone%2C%20P.J.%20%282004%29%20%26%23x201C%3BComparative%20analysis%20of%20in%20vitro%20contracture%20tests%20with%20ryanodine%20and%20a%20combination%20of%20ryanodine%20with%20either%20halothane%20or%20caffeine%3A%20a%20comparative%20investigation%20in%20malignant%20hyperthermia%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BActa%20anaesthesiologica%20Scandinavica%26lt%3B%5C%2Fi%26gt%3B%2C%2048%288%29%2C%20pp.%201019%26%23x2013%3B1027.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fj.0001-5172.2004.00461.x%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fj.0001-5172.2004.00461.x%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparative%20analysis%20of%20in%20vitro%20contracture%20tests%20with%20ryanodine%20and%20a%20combination%20of%20ryanodine%20with%20either%20halothane%20or%20caffeine%3A%20a%20comparative%20investigation%20in%20malignant%20hyperthermia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%22%2C%22lastName%22%3A%22Guis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Monnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%22%2C%22lastName%22%3A%22Kozak-Ribbens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Lunardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Ghattas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J-P%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%20J%22%2C%22lastName%22%3A%22Cozzone%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20diagnosis%20of%20susceptibility%20to%20malignant%20hyperthermia%20%28MH%29%20is%20currently%20performed%20on%20muscle%20biopsies%20subjected%20to%20halothane-caffeine%20in%20vitro%20contracture%20tests%20%28IVCTs%29.%20There%20is%20a%20consensus%20on%20our%20need%20to%20improve%20the%20diagnostic%20potential%20of%20IVCTs%20if%20we%20are%20to%20maximize%20the%20information%20available%20for%20research%20and%20diagnosis%20in%20MH.%20This%20study%20was%20designed%20as%20a%20pilot%20comparative%20study%20and%20we%20aimed%20at%20comparing%20the%20ryanodine%20test%20and%20new%20tests%20using%20a%20combination%20of%20ryanodine%2C%20halothane%20and%20caffeine.%5CnMETHODS%3A%20One%20hundred%20and%20thirty-two%20subjects%20%2852%20MHS%20and%2080%20MHN%29%20were%20included%20in%20this%20study%20and%20new%20IVCTs%20were%20performed%20in%20additional%20muscle%20biopsy%20specimens.%20The%20contracture%20time-course%20was%20compared%20considering%20the%20onset%20time%20of%20contracture%20%28OT%29%20and%20the%20time%20to%20reach%20a%2010%20mN%20contracture%20%2810T%29.%20Cut-off%20values%20were%20determined%20using%20ROC%20analyses.%5CnRESULTS%3A%20For%20the%20ryanodine%20test%2C%20sensitivity%20and%20specificity%20calculated%20for%20OT%20were%2084.6%25%20and%2090.4%25%2C%20respectively%2C%20and%20were%20better%20than%20those%20obtained%20using%2010T.%20Combined%20tests%20using%20either%20caffeine%20and%20ryanodine%20or%20halothane%20and%20ryanodine%20did%20provide%20higher%20sensitivities%20%28from%2085.3%20to%2093.9%25%29.%20A%20better%20specificity%20was%20only%20observed%20for%20the%20IVC%20tests%20combining%20halothane%20%28cumulated%29%20and%20caffeine%20both%20with%20ryanodine%20%2893.9%25%20for%20both%29.%20The%20largest%20sensitivity%20was%20observed%20when%20halothane%20was%20used%20as%20a%20bolus%20and%20combined%20with%20ryanodine.%20The%20specificity%20was%20always%20larger%20with%20the%20combined%20tests%20as%20compared%20to%20the%20test%20using%20ryanodine%20alone%20%28from%2079.1%20to%2090.9%25%29.%20This%20superiority%20was%20confirmed%2C%20at%20least%20in%20part%2C%20when%20comparing%20genetic%20investigations%20and%20the%20results%20of%20new%20tests%20in%20a%20subgroup%20of%20subjects.%5CnCONCLUSIONS%3A%20This%20pilot%20study%20showed%20a%20clear%20diagnostic%20potential%20for%20new%20IVC%20tests%20combining%20halothane%2C%20the%20triggering%20agent%20of%20MH%2C%20and%20ryanodine%20acting%20at%20the%20calcium%20release%20channel%2C%20and%20should%20be%20considered%20as%20a%20first%20step%20in%20the%20investigation%20of%20combined%20tests.%22%2C%22date%22%3A%22Sep%202004%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fj.0001-5172.2004.00461.x%22%2C%22ISSN%22%3A%220001-5172%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%224ZGX55W3%22%2C%226BEMAGEW%22%5D%2C%22dateModified%22%3A%222024-10-29T10%3A45%3A29Z%22%7D%7D%5D%7D
Guenoun, D., Wirth, T., Roche, D., Michel, C.P., Daudé, P., Ogier, A.C., Chagnaud, C., Mattei, J.P., Pini, L., Guye, M., Ollivier, M., Bendahan, D. and Guis, S. (2023) “Ultra-high field magnetic resonance imaging of the quadriceps tendon enthesis in healthy subjects,” Surgical and Radiologic Anatomy, 45(8), pp. 1049–1054. Available at: https://doi.org/10.1007/s00276-023-03175-y.
Trojani, M.-C., Chorin, F., Gerus, P., Breuil, V., Michel, C., Guis, S., Bendahan, D. and Roux, C. (2022) “Concentric or eccentric physical activity for patients with symptomatic osteoarthritis of the knee: a randomized prospective study,” Therapeutic Advances in Musculoskeletal Disease, 14, p. 1759720X221102805. Available at: https://doi.org/10.1177/1759720X221102805.
Guedj, E., Campion, J.Y., Dudouet, P., Kaphan, E., Bregeon, F., Tissot-Dupont, H., Guis, S., Barthelemy, F., Habert, P., Ceccaldi, M., Million, M., Raoult, D., Cammilleri, S. and Eldin, C. (2021) “18F-FDG brain PET hypometabolism in patients with long COVID,” European Journal of Nuclear Medicine and Molecular Imaging, 48(9), pp. 2823–2833. Available at: https://doi.org/10.1007/s00259-021-05215-4.
Molto, A., Gossec, L., Poiraudeau, S., Claudepierre, P., Soubrier, M., Fayet, F., Wendling, D., Gaudin, P., Dernis, E., Guis, S., Pouplin, S., Ruyssen-Witrand, A., Chales, G., Mariette, X., Beauvais, C., Combe, B., Flipo, R.-M., Richette, P., Chary-Valckenaere, I., Saraux, A., Sibilia, J., Schaeverbeke, T. and Dougados, M. (2021) “Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA),” Rheumatology (Oxford, England), 60(2), pp. 888–895. Available at: https://doi.org/10.1093/rheumatology/keaa480.
Soldati, E., Escoffier, L., Gabriel, S., Ogier, A.C., Chagnaud, C., Mattei, J.P., Cammilleri, S., Bendahan, D. and Guis, S. (2021) “Assessment of in vivo bone microarchitecture changes in an anti-TNFα treated psoriatic arthritic patient,” PloS One, 16(5), p. e0251788. Available at: https://doi.org/10.1371/journal.pone.0251788.
Falgarone, G., Pamoukdjian, F., Cailhol, J., Giocanti-Auregan, A., Guis, S., Bousquet, G., Bouchaud, O. and Seror, O. (2020) “Lung ultrasound is a reliable diagnostic technique to predict abnormal CT chest scan and to detect oxygen requirements in COVID-19 pneumonia,” Aging, 12(20), pp. 19945–19953. Available at: https://doi.org/10.18632/aging.104150.
Molto, A., Gossec, L., Poiraudeau, S., Claudepierre, P., Soubrier, M., Fayet, F., Wendling, D., Gaudin, P., Dernis, E., Guis, S., Pouplin, S., Ruyssen, A., Chales, G., Mariette, X., Beauvais, C., Combe, B., Flipo, R.-M., Richette, P., Chary-Valckenaere, I., Saraux, A., Sibilia, J., Schaeverbeke, T. and Dougados, M. (2020) “Evaluation of the impact of a nurse-led program of systematic screening of comorbidities in patients with axial spondyloarthritis: The results of the COMEDSPA prospective, controlled, one year randomized trial,” Seminars in Arthritis and Rheumatism, 50(4), pp. 701–708. Available at: https://doi.org/10.1016/j.semarthrit.2020.05.012.
Guenoun, D., Pithioux, M., Souplet, J.-C., Guis, S., Le Corroller, T., Fouré, A., Pauly, V., Mattei, J.-P., Bernard, M., Guye, M., Chabrand, P., Champsaur, P. and Bendahan, D. (2020) “Assessment of proximal femur microarchitecture using ultra-high field MRI at 7 Tesla,” Diagnostic and Interventional Imaging, 101(1), pp. 45–53. Available at: https://doi.org/10.1016/j.diii.2019.06.013.
Cammilleri, S., Gabriel, S., Le Troter, A., Chagnaud, C., Mattei, J.P., Bendahan, D. and Guis, S. (2019) “Knee psoriatic enthesitis assessed using positron emission tomography (PET) - FNa merged to ultrahigh field magnetic resonance imaging (UHF-MRI),” Joint Bone Spine, 86(3), pp. 387–388. Available at: https://doi.org/10.1016/j.jbspin.2019.01.002.
Gossec, L., Soubrier, M., Foissac, F., Molto, A., Richette, P., Beauvais, C., Ruyssen-Witrand, A., Perdriger, A., Chary-Valckenaere, I., Mouterde, G., Dernis, E., Euller-Ziegler, L., Flipo, R.-M., Gilson, M., Guis, S., Mariette, X., Pouplin, S., Marhadour, T., Schaeverbeke, T., Sordet, C., Fayet, F. and Dougados, M. (2019) “Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients,” RMD open, 5(2), p. e000914. Available at: https://doi.org/10.1136/rmdopen-2019-000914.
Benzaquen, M., Flachaire, B., Rouby, F., Berbis, P. and Guis, S. (2018) “Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy,” Rheumatology International, 38(7), pp. 1297–1299. Available at: https://doi.org/10.1007/s00296-018-4034-0.
Guenoun, D., Fouré, A., Pithioux, M., Guis, S., Le Corroller, T., Mattei, J.-P., Pauly, V., Guye, M., Bernard, M., Chabrand, P., Champsaur, P. and Bendahan, D. (2017) “Correlative Analysis of Vertebral Trabecular Bone Microarchitecture and Mechanical Properties: A Combined Ultra-high Field (7 Tesla) MRI and Biomechanical Investigation,” Spine, 42(20), pp. E1165–E1172. Available at: https://doi.org/10.1097/BRS.0000000000002163.
Balandraud, N., Texier, G., Massy, E., Muis-Pistor, O., Martin, M., Auger, I., Guzian, M.-C., Guis, S., Pham, T. and Roudier, J. (2017) “Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study,” PloS One, 12(2), p. e0171623. Available at: https://doi.org/10.1371/journal.pone.0171623.
Gottenberg, J.-E., Brocq, O., Perdriger, A., Lassoued, S., Berthelot, J.-M., Wendling, D., Euller-Ziegler, L., Soubrier, M., Richez, C., Fautrel, B., Constantin, A.L., Mariette, X., Morel, J., Gilson, M., Cormier, G., Salmon, J.H., Rist, S., Lioté, F., Marotte, H., Bonnet, C., Marcelli, C., Sellam, J., Meyer, O., Solau-Gervais, E., Guis, S., Ziza, J.-M., Zarnitsky, C., Chary-Valckenaere, I., Vittecoq, O., Saraux, A., Pers, Y.-M., Gayraud, M., Bolla, G., Claudepierre, P., Ardizzone, M., Dernis, E., Breban, M.A., Fain, O., Balblanc, J.-C., Aberkane, O., Vazel, M., Back, C., Candon, S., Chatenoud, L., Perrodeau, E., Sibilia, J. and Ravaud, P. (2016) “Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial,” JAMA, 316(11), pp. 1172–1180. Available at: https://doi.org/10.1001/jama.2016.13512.
Mege, D., Cammilleri, S., Mundler, O., Dignat-George, F., Dubois, C., Panicot-Dubois, L. and Guis, S. (2016) “Circulating microparticles bearing Fibrin associated with whole-body 18FDG-PET: diagnostic tools to detect paraneoplastic polymyalgia rheumatica,” Rheumatology International, 36(8), pp. 1099–1103. Available at: https://doi.org/10.1007/s00296-016-3510-7.
Montoya, J., Matta, N.B., Suchon, P., Guzian, M.C., Lambert, N.C., Mattei, J.P., Guis, S., Breban, M., Roudier, J. and Balandraud, N. (2016) “Patients with ankylosing spondylitis have been breast fed less often than healthy controls: a case-control retrospective study,” Annals of the Rheumatic Diseases, 75(5), pp. 879–882. Available at: https://doi.org/10.1136/annrheumdis-2015-208187.
Guis, S., Berbis, P., Stephan, D., Bertin, D., Amatore, F., Balandraud, N., Lesavre, N. and Desplat-Jégo, S. (2016) “TWEAK-binding autoantibodies are generated during psoriatic arthritis and are not influenced by anti-TNF therapy,” Journal of Translational Medicine, 14(1), p. 185. Available at: https://doi.org/10.1186/s12967-016-0923-8.
Zink, J.-V., Souteyrand, P., Guis, S., Chagnaud, C., Fur, Y.L., Militianu, D., Mattei, J.-P., Rozenbaum, M., Rosner, I., Guye, M., Bernard, M. and Bendahan, D. (2015) “Standardized quantitative measurements of wrist cartilage in healthy humans using 3T magnetic resonance imaging,” World Journal of Orthopedics, 6(8), pp. 641–648. Available at: https://doi.org/10.5312/wjo.v6.i8.641.
Silvy, F., Bertin, D., Bardin, N., Auger, I., Guzian, M.-C., Mattei, J.-P., Guis, S., Roudier, J. and Balandraud, N. (2015) “Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics,” PloS One, 10(7), p. e0134218. Available at: https://doi.org/10.1371/journal.pone.0134218.
Cheung, P.P., Dougados, M., Andre, V., Balandraud, N., Chalès, G., Chary-Valckenaere, I., Dernis, E., Gill, G., Gilson, M., Guis, S., Mouterde, G., Pavy, S., Pouyol, F., Marhadour, T., Richette, P., Ruyssen-Witrand, A., Soubrier, M., Nguyen, M. and Gossec, L. (2014) “The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis,” Joint, Bone, Spine: Revue Du Rhumatisme, 81(2), pp. 154–159. Available at: https://doi.org/10.1016/j.jbspin.2013.06.006.
Zink, J., Souteyrand, P., Guis, S., Chagnaud, C., Le Fur, Y., Militianu, D., Mattei, J.P., Rozenbaum, M., Rosner, I., Boudinet, H., Bernard, M. and Bendahan, D. (2013) “Semi-Automatic Quantitative Investigation of Wrist Cartilage in Humans Using 3t Mri,” Annals of the Rheumatic Diseases, 72, pp. 1018–1019.
Guis, S., Mattei, J.-P. and Bendahan, D. (2013) “Toxic myopathies,” Joint, bone, spine: revue du rhumatisme, 80(3), pp. 231–233. Available at: https://doi.org/10.1016/j.jbspin.2012.10.008.
Cheung, P.P., Dougados, M., Andre, V., Balandraud, N., Chales, G., Chary-Valckenaere, I., Chatelus, E., Dernis, E., Gill, G., Gilson, M., Guis, S., Mouterde, G., Pavy, S., Pouyol, F., Marhadour, T., Richette, P., Ruyssen-Witrand, A., Soubrier, M. and Gossec, L. (2013) “Improving agreement in assessment of synovitis in rheumatoid arthritis,” Joint, Bone, Spine: Revue Du Rhumatisme, 80(2), pp. 155–159. Available at: https://doi.org/10.1016/j.jbspin.2012.07.014.
Cammilleri, S., Guzian, M.C., Mattei, J.-P., Mundler, O. and Guis, S. (2013) “Whole-Body (18) FDG-PET in an Arthritis Paraneoplastic Syndrome Revealed an Underlying Hematological Neoplasm,” Case Reports in Medicine, 2013, p. 594704. Available at: https://doi.org/10.1155/2013/594704.
D’Agostino, M.-A., Saraux, A., Chary-Valckenaere, I., Marcelli, C., Guis, S., Gaudin, P., Aegerter, P., Jousse-Joulin, S., Loeuille, D., Judet, O., Lecoq, B., Hacquard-Bouder, C., Grange, L., Guzian, M.C., Blum, A., Chagnaud, C., Leboime, A., Monnet, D., Rat, A.-C., Timsit, M.A., Said-Nahal, R. and Breban, M. (2012) “Can we improve the diagnosis of spondyloarthritis in patients with uncertain diagnosis? The EchoSpA prospective multicenter French cohort,” Joint, Bone, Spine: Revue Du Rhumatisme, 79(6), pp. 586–590. Available at: https://doi.org/10.1016/j.jbspin.2012.02.007.
Devauchelle-Pensec, V., D’Agostino, M.A., Marion, J., Lapierre, M., Jousse-Joulin, S., Colin, D., Chary-Valckenaere, I., Marcelli, C., Loeuille, D., Aegerter, P., Guis, S., Gaudin, P., Breban, M., Saraux, A. and Study Group of Spondylarthritis (2012) “Computed tomography scanning facilitates the diagnosis of sacroiliitis in patients with suspected spondylarthritis: results of a prospective multicenter French cohort study,” Arthritis and Rheumatism, 64(5), pp. 1412–1419. Available at: https://doi.org/10.1002/art.33466.
Bonnet, N., Guis, S., Drancourt, M., Brouqui, P. and Berbis, P. (2011) “Borreliosis in a patient treated with anti-TNFα therapy: first case,” Journal of the European Academy of Dermatology and Venereology: JEADV, 25(3), pp. 367–368. Available at: https://doi.org/10.1111/j.1468-3083.2010.03724.x.
Faucher, B., Stein, P., Granel, B., Weiller, P.-J., Disdier, P., Serratrice, J., Harlé, J.R., Durand, J.M., Frances, Y., Guis, S., Pham, T., Bardin, N. and Sanmarco, M. (2010) “Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma,” European Journal of Internal Medicine, 21(2), pp. 114–117. Available at: https://doi.org/10.1016/j.ejim.2010.01.004.
Bonnet, N., Guis, S., Koeppel, M.-C., Roudier, J., Grimaud, J.-C., Jean-Pastor, M.-J. and Berbis, P. (2010) “[Cutaneous events during anti-TNF alpha therapy: a prospective observational study of 41 cases],” Annales De Dermatologie Et De Vénéréologie, 137(1), pp. 12–20. Available at: https://doi.org/10.1016/j.annder.2009.12.003.
Rak, J.M., Maestroni, L., Balandraud, N., Guis, S., Boudinet, H., Guzian, M.C., Yan, Z., Azzouz, D., Auger, I., Roudier, C., Martin, M., Didelot, R., Roudier, J. and Lambert, N.C. (2009) “Transfer of the shared epitope through microchimerism in women with rheumatoid arthritis,” Arthritis and Rheumatism, 60(1), pp. 73–80. Available at: https://doi.org/10.1002/art.24224.
Charpin, C., Guis, S., Colson, P., Borentain, P., Mattéi, J.-P., Alcaraz, P., Balandraud, N., Thomachot, B., Roudier, J. and Gérolami, R. (2009) “Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients,” Arthritis Research & Therapy, 11(6), p. R179. Available at: https://doi.org/10.1186/ar2868.
Guis, S., Schiano de Colella, J.-M., Bonnet, N., Andrac-Meyer, L., Balandraud, N., Mattei, J.-P., Franck, B., Roudier, C., Roudier, J. and Berbis, P. (2008) “Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept,” European journal of dermatology: EJD, 18(4), pp. 474–476. Available at: https://doi.org/10.1684/ejd.2008.0457.
Charpin, C., Balandraud, N., Guis, S., Roudier, C., Toussirot, E., Rak, J., Lambert, N., Martin, M., Reviron, D., Roudier, J. and Auger, I. (2008) “HLA-DRB1*0404 is strongly associated with high titers of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis,” Clinical and Experimental Rheumatology, 26(4), pp. 627–631.
Guis, S., Balandraud, N., Bouvenot, J., Auger, I., Toussirot, E., Wendling, D., Mattei, J.-P., Nogueira, L., Mugnier, B., Legeron, P., Landt, O., Serre, G., Roudier, J. and Roudier, C. (2007) “Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis,” Arthritis and Rheumatism, 57(8), pp. 1426–1430. Available at: https://doi.org/10.1002/art.23092.
Auger, I., Roudier, C., Guis, S., Balandraud, N. and Roudier, J. (2007) “HLA-DRB1*0404 is strongly associated with anticalpastatin antibodies in rheumatoid arthritis,” Annals of the Rheumatic Diseases, 66(12), pp. 1588–1593. Available at: https://doi.org/10.1136/ard.2006.067231.
Guis, S. and Pellissier, J.F. (2007) “[Foreword - macrophage mediated myofasciites],” Revue Neurologique, 163(10), pp. 979–980.
Balandraud, N., Guis, S., Meynard, J.B., Auger, I., Roudier, J. and Roudier, C. (2007) “Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis,” Arthritis and Rheumatism, 57(5), pp. 762–767. Available at: https://doi.org/10.1002/art.22783.
Charpin, C., Berbis, P., Schmitz, J., Boudinet, H., Mattei, J.-P., Balandraud, N., Chagnaud, C., Roudier, J. and Guis, S. (2007) “Neurofibromatosis type 1 with sciatica,” Joint, Bone, Spine: Revue Du Rhumatisme, 74(3), pp. 300–301. Available at: https://doi.org/10.1016/j.jbspin.2006.09.013.
Mattei, J.P., Fur, Y.L., Cuge, N., Guis, S., Cozzone, P.J. and Bendahan, D. (2006) “Segmentation of fascias, fat and muscle from magnetic resonance images in humans: the DISPIMAG software,” Magma (New York, N.Y.), 19(5), pp. 275–279. Available at: https://doi.org/10.1007/s10334-006-0051-1.
Guis, S., Figarella-Branger, D., Mattei, J.P., Nicoli, F., Le Fur, Y., Kozak-Ribbens, G., Pellissier, J.F., Cozzone, P.J., Amabile, N. and Bendahan, D. (2006) “In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects,” Arthritis and rheumatism, 55(4), pp. 551–557. Available at: https://doi.org/10.1002/art.22100.
Figarella-Branger, D., Schleinitz, N., Boutière-Albanèse, B., Camoin, L., Bardin, N., Guis, S., Pouget, J., Cognet, C., Pellissier, J.-F. and Dignat-George, F. (2006) “Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies,” The Journal of Rheumatology, 33(8), pp. 1623–1630.
Bendahan, D., Mattei, J.P., Guis, S., Kozak-Ribbens, G. and Cozzone, P.J. (2006) “[Non-invasive investigation of muscle function using 31P magnetic resonance spectroscopy and 1H MR imaging],” Revue neurologique, 162(4), pp. 467–484.
Alcaraz, P., Aubran, C., Jaoua, S., Roudier, C., Mattei, J.P., Announ, N., Chagnaud, C., Roudier, J. and Guis, S. (2006) “Calcaneal osteomyelitis due to fistulization of an ulcerated rheumatoid nodule,” Joint, Bone, Spine: Revue Du Rhumatisme, 73(1), pp. 102–104. Available at: https://doi.org/10.1016/j.jbspin.2005.01.006.
Auger, I., Sebbag, M., Vincent, C., Balandraud, N., Guis, S., Nogueira, L., Svensson, B., Cantagrel, A., Serre, G. and Roudier, J. (2005) “Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen,” Arthritis and Rheumatism, 52(11), pp. 3424–3432. Available at: https://doi.org/10.1002/art.21391.
Guis, S., Mattei, J.-P., Cozzone, P.J. and Bendahan, D. (2005) “Pathophysiology and clinical presentations of rhabdomyolysis,” Joint, bone, spine: revue du rhumatisme, 72(5), pp. 382–391. Available at: https://doi.org/10.1016/j.jbspin.2004.04.010.
Poullin, P., Announ, N., Mugnier, B., Guis, S., Roudier, J. and Lefèvre, P. (2005) “Protein A-immunoadsorption (Prosorba column) in the treatment of rheumatoid arthritis,” Joint, Bone, Spine: Revue Du Rhumatisme, 72(2), pp. 101–103. Available at: https://doi.org/10.1016/j.jbspin.2004.02.009.
Guis, S., Mattei, J.-P., Pellissier, J.-F., Nicoli, F., Figarella-Branger, D., Le Fur, Y., Kaplanski, G., Pelletier, J., Harle, J.-R., Cozzone, P.J. and Bendahan, D. (2004) “MRI and 31PMR spectroscopy investigations of muscle function disclose no abnormality in macrophagic myofasciitis,” The Journal of rheumatology, 31(11), pp. 2313–2314.
Bendahan, D., Guis, S., Monnier, N., Kozak-Ribbens, G., Lunardi, J., Ghattas, B., Mattei, J.-P. and Cozzone, P.J. (2004) “Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia,” Acta anaesthesiologica Scandinavica, 48(8), pp. 1019–1027. Available at: https://doi.org/10.1111/j.0001-5172.2004.00461.x.